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1 
Introduction and Aims of Research  
 
1.1 INTRODUCTION 
Primary Adenocarcinoma of the duodenum is a rare condition, accounting between 
0, 3% and 0, 5% of all gastrointestinal malignancies 1-3. 
Despite the duodenum is representing less than 10 % of the total length of the small 
bowel, this organ is the site of between 25% and 45% of the small bowel cancers 4. 
However cancer of the duodenum appeared to be more frequent in the proximity of 
the Ampulla of Vater periampullary area 5, about 45 % of them demonstrated to arise 
in third and in fourth portions of this organ. Since the symptoms of this cancer are 
non-specific and similar to other benign conditions, the diagnosis is often difficult and 
delayed. 
Nonetheless, duodenal carcinoma has a reported 5-year survival rate for resected 
tumours   between 25% and 75% 6-10 which is significantly better than that for cancer 
of the ampulla (46%) 11 and the head of pancreas (10%) 12, 13. 
In the last decade different studies evaluated the correlations between clinical, 
pathological and treatment variables in order to identified specific prognostic factors 
associated with survival 14-19. 
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Those recent studies showed that histological grade, transmural involvement, tumour 
size, lymph node involvement and distant metastasis can influence the survival in 
patients with duodenal adenocarcinoma. 
However, due to a low incidence of this disease in the general population, the debate 
on prognostic factors in duodenal adenocarcinoma is still open. Therefore, questions 
have been raised especially on the prognostic significance of the absolute number 
and ratio of involved lymph nodes. A recent study has led an increased interest on 
perineural invasion as single independent prognostic factor for patients with primary 
duodenal cancer 20. 
1.2 Aims of research 
The aim of this thesis was to improve understanding of specific prognostic factors 
associated to survival in primary duodenal adenocarcinoma.   
A retrospective review of 37 patients diagnosed with primary duodenal adenocarci-
noma between 1989 and 2009 was performed at Hepato-pancreatico-biliary depart-
ment, General Surgery B, Verona University, Borgo Roma Hospital. Data were ac-
quired then analysed for impact on recurrence and 5-year overall survival rate. 
From this retrospective study, evidence will be generated to improve knowledge on 
potential prognostic factors in primary duodenal adenocarcinoma. 
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2 
Anatomy, Physiology of the Duodenum and 
Embryology of Midgut 
 
2.1 ANATOMY OF THE DUODENUM 
The length of the duodenum varies from 20 to 25 cm and is the shortest and 
widest part of the small bowel. The duodenum extends up to the duodenuoje-
junal junction and lies mostly in the upper retroperitoneum with only the proxi-
mal 2.5 cm of its length located in the intraperitoneal cavity. The duodenum is 
anatomically divided into four parts and curves in the shape of the letter C 
around the head of the pancreas. 
2.1.1 FIRST (SUPERIOR) PART 
The first is the most mobile part of the duodenum and is about 5 cm long. The 
first 2 cm of the duodenum is frequently referred to as the duodenal “cap” since 
is often visible in the plain radiographs of the abdomen as an isolated triangular 
gas shadow to the right of the first or second lumbar vertebra. 
The first part of the duodenum lies anterior to the gastroduodenal artery, com-
mon bile duct and portal vein and anterosuperior to the head and neck of the 
pancreas. 
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The junction of the first and second parts of the duodenum lies posterior to the 
neck of the gallbladder. 
2.1.2 SECOND (DESCENDING) PART 
The second part of the duodenum is 8-10 cm long. It starts at the superior duo-
denal flexure and runs inferiorly in a gentle curve, convex to the right side of the 
vertebral column and extending to the lower border of the third lumbar vertebral 
body. It is covered by peritoneum only on the upper anterior surface, lies poste-
rior to the neck of the gallbladder and the right lobe of the liver at its start, and is 
crossed transversally by the transverse colon. The common bile duct and pan-
creatic duct enter the medial wall of this portion of duodenum obliquely and 
usually united to form the common hepatopancreatic ampulla. The narrow distal 
end opens on the summit of the major duodenal papilla called ampulla of Vater 
which is situated on the posteromedial wall of the second part, 8-10 cm distal to 
the pylorus. 
2.1.3THIRD (HORIZONTAL) PART 
The third portion of the duodenum starts from the inferior duodenal flexure and 
is approximately 10 cm long. It runs from the right side of the lower border of the 
third lumbar vertebra,  angled slightly superiorly, across to the left, anterior to 
the inferior vena cava, becoming continuous with the forth part in front of the 
abdominal aorta. 
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It lies posterior to the transverse colon, the origin of the small bowel mesentery 
and the superior mesenteric vessels.  
The third part is anterior to the right ureter, right psoas muscle, right gonadal 
vessels, inferior vena cava and abdominal aorta, and inferior to the head of the 
pancreas. 
2.1.4 FOURTH (ASCENDING) PART 
The fourth part of the duodenum is 2.5 cm long. It stars just to the left of the 
aorta, runs superiorly and laterally to the level of the level of the upper border of 
the second lumbar vertebra, and then turns sharply anteroinferiorly at the duo-
denojejunal flexure to become continuous with the jejunum. At its left lateral 
end, the forth part becomes covered in peritoneum on its superior and inferior 
surfaces, such that it is suspended by a double fold of peritoneum, the ligament 
of Treitz, at the start of the duodenuojejunal flexure. 
2.1.5 BLOOD SUPPLY AND LYMPHATIC DRAINAGE 
The main vessels supplying the duodenum are the superior and inferior pan-
creaticoduodenal arteries. The first and the second parts also receive contribu-
tions from several sources including the right gastric, supraduodenal, right gas-
troepiploic, hepatic and gastroduodenal arteries. 
The duodenal veins drain ultimately into the portal vein through the superior and 
inferior pancreaticoduodenal veins.  
 
Primary Adenocarcinoma of the Duodenum  Anatomy, Physiology & Embryology   
 
 
6 
 
Duodenal lymphatics run anterior and posterior pancreatic nodes that lie in the 
anterior and posterior grooves between the head of the pancreas and the duo-
denum: these nodes drain widely into the suprapyloric, infrapyloric, hepatoduo-
denal, common hepatic and superior mesenteric nodes. 
2.1.6 INNERVATION 
The duodenum is innervated by both parasympathetic and sympathetic neu-
rones. 
Preganglionic sympathetic axons originate from neurons in the interome-
diolateral columns of the grey matter in the fifth to the 12th thoracic spinal seg-
ments. They travel via greater and lesser splanchnic nerves to the celiac plexus 
where they synapse on neurones in the coeliac ganglion. The sympathetic 
nerves are vasoconstrictor to the duodenal vasculature and inhibitor to the duo-
denal musculature. 
The preganglionic parasympathetic supply is carried by vagal axons that are 
distributed via celiac plexus and which synapse on the neurones in the duode-
nal wall. The parasympathetic supply is secretomotor to the duodenal mucosa 
and motor to the duodenal musculature. The sympathetic nerves are vasocon-
strictor to the duodenal vasculature and inhibitory to the duodenal musculature. 
2.1.7 HISTOLOGY OF INTESTINAL WALL  
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The mucosa of the duodenum and small bowel is thrown into a series of folds 
by the plicate are the valvulae conniventes. This greatly increases the surface 
area available for absorption within the small bowel.  
The mucosa of the small bowel contains intestinal villi which are covered by 
simple columnar epithelium and broken into microvilli. The wall of the small in-
testine is divided into the lamina propria, and this is divided from the submucosa 
by the muscularis mucosae. Within the lamina propria there is an extensive 
network of capillaries which transports respiratory gases and absorb material to 
the hepatoportal circulation.  
In addition, there are capillaries and nerve endings within the lamina propria 
and each villus also contains a terminal lymphatic called a lacteal. The name 
lacteal refers to the cloudy appearance of the lymph contained within these 
channels. The lacteals themselves transport materials that fail to enter the local 
capillaries because they are unable to cross the capillary wall. Examples would 
be of fatty acids and proteins which are too large to diffuse into the blood-
stream. These lipoproteins form small partials called chylomicrons which pass 
through the lymphatic system and account for the milky appearance within the 
lacteal. 
2.1.7.1.1 INTESTINAL CRYPTS 
 Within the columnar epithelium there are goblet cells which produce mucus 
onto the intestinal surfaces. At the base of the villi there are also found en-
trances to the intestinal crypts. These extend deep into the underlying lamina 
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propria. Within the intestinal crypts there are a number of different cell popula-
tions including stem-cell divisions which continue to produce new generations of 
columnar and goblet cells.  
These new cells are continuously displaced towards the intestinal surface and 
within a few days will reach the tip of the villi, where they will be shed or exfoli-
ated into the intestinal lumen. It is this process of exfoliation of the intestinal 
cells which ensures that the epithelial surface continues to be renewed. This 
also adds intracellular enzymes to the intestinal contents. One of these en-
zymes would be enterokinase, which although it does not does not directly par-
ticipate in the digestion of food, is important because it activates proenzymes 
secreted by the pancreas. Cells within the intestinal crypts also contain entero-
endocrine cells.  
These are responsible for the production of several intestinal hormones includ-
ing cholecystokinin and secretin. 
2.2 PHYSIOLOGY OF DUODENUM 
The duodenum has very little absorptive function and acts mainly to neutralise 
the acidic contents delivered to it by the stomach. The duodenum receives the 
chyme from the stomach and its essential function is to buffer the gastric acid 
and enzymes before delivering the contents to the jejunum. The histological 
characterisation of the duodenum reveals abundant presence of mucus secret-
ing glands. These submucosal glands, known as Brunner’s glands, assist in the 
production of copious amounts of mucus. The secretion of this mucus is to pro-
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tect the duodenal mucosa and also to neutralise the acid pH of the chyme. The 
submucosal glands are most abundant in the proximal duodenum and decrease 
in number towards the jejunum.  
The pH of the duodenal contents rises from a pH of 1–2 to 7–8 by the time it is 
delivered to the jejunum. In addition, the chyme is diluted by mixing with the in-
testinal, pancreatic and hepatic secretions. The duodenal ampulla lies within the 
wall of the second part of the duodenum and allows for the delivery of bile and 
pancreatic enzymes to initiate the digestion and breakdown of the chyme. Ab-
sorption may occur; it is more effective under these conditions and the increase 
in the surface area of the duodenum in its third and fourth parts supports this 
increased absorptive capacity. 
2.2.1 INTESTINAL HORMONES  
The enteroendocrine cells within the duodenum produce hormones which coor-
dinate the secretory activity of the stomach, duodenum, liver and pancreas.  
Enterocrinin is a hormone which is released by the duodenal mucosa when the 
acid chyme from the stomach enters the small intestine. There are many other 
hormones secreted which have both primary and secondary effects, and which 
act in a complementary fashion. The three most important hormones involved in 
the regulatory activity of the small intestine are secretin, cholecystokinin and the 
glucose-dependent insulinotropic peptide. 
2.2.1.1 Secretin 
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Secretin is produced in response to the presence of acid within the duodenum.  
The primary effect of secretin is to increase the production of water and buffers 
by the pancreas and liver. It also has an effect on stimulating the duodenal 
submucosal glands. 
2.2.1.2 Cholecystokinin (CCK) 
The duodenal mucosa is stimulated to produce cholecystokinin when chyme 
arrives within the lumen of the duodenum and particularly when it contains lipids 
and partially digested proteins. This hormone has a target effect both on the 
pancreas and on the liver. The pancreas is stimulated to produce and secrete 
digestive enzymes, and the hormone also increases the passage of bile by 
stimulating the gall bladder to contract. The net effect of cholecystokinin is to 
increase the secretion of pancreatic enzymes and stimulate the production of 
bile. However, in high concentration both secretin and cholecystokinin have the 
additional effect of producing gastric motility and secretions. 
2.2.1.2 Glucose-dependent Insulinotropic Peptide (GIP) 
This peptide is released by the duodenal mucosa in response to fats and glu-
cose entering the duodenum.  
This peptide stimulates the release of insulin from the pancreatic islet cells, al-
though at high concentration it can also inhibit gastric activity. (Originally this 
was named the gastric inhibitory peptide)  
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2.2.1.3 Vasoactive Intestinal Peptide (VIP) 
Several other hormones are produced in small quantities in response to chyme 
entering the duodenum.  
For example, relatively large amounts of undigested proteins will stimulate the 
release of gastrin by the duodenal cells. Vasoactive intestinal peptide or VIP is 
also produced and it stimulates the secretion of the intestinal glands whilst in-
hibiting acid production within the stomach. Previously, it was considered that 
the enzyme called enterogastrin was responsible for inhibiting gastric activity. 
However, it is now considered that this inhibition of gastric motility is the product 
of GIP and VIP. The number and diversity of the hormones produced by the 
small bowel are well recognised, but poorly understood. Many of the hormones 
have a similar chemical structure and it is difficult to differentiate the primary ef-
fects of these various hormones. Analysis has led to an increased number of 
hormones being identified, although their specific functions are poorly under-
stood 21. 
 
2.3 EMBRIOLOGY OF THE MIDGUT 
In the adult the midgut starts immediately distal to the point where the bile duct 
enters the duodenum and it terminates at the junction of the proximal two-thirds 
of the transverse colon with a distal third.  
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The superior mesenteric artery supplies the entire length of the midgut. 
 Within the 5-week-old embryo the midgut is suspended by a short mesentery 
from the posterior abdominal wall and it communicates with the yolk sac by way 
of the 
 vitello-intestinal duct. At the apex of the midgut loop there is a connection with 
the yolk sac via the vitelline duct.  
The proximal or cephalic limb of the loop becomes the distal part of the duode-
num, the jejunum and part of the ileum, and the cordal or distal portion of the 
loop becomes the ileum, caecum, appendix, ascending and proximal transverse 
colon. With the rapid growth and expansion of the liver and the elongation of the 
midgut, the abdominal cavity becomes too small to contain the intestinal loops. 
For a period during the sixth week of development, the intestinal loops enter an 
extra-embryonic cavity within the umbilical cord; this is considered to be a 
physiological umbilical herniation.  
By the tenth week the herniated intestinal loops are returning to the abdominal 
cavity. The precise factors responsible for this are not known although as the 
mesonephric kidney regresses and there is a reduced growth of the liver with 
some expansion of the abdominal cavity, space becomes available to allow for 
the return of the midgut to the abdomen.  
As the midgut retracts into the abdomen it also rotates and with the expansion 
of the caecal bud, which appears around the sixth week, the characteristic 
placement of the midgut within the abdominal cavity occurs.  
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The distal midgut expands and there is some separation into the small and 
large intestine. A small narrow diverticulum is formed from the caecal bud which 
develops into the appendix. 
 The mesenteries of the intestinal loops are produced during the changes and 
rotation of the midgut around the superior mesentery vessels.  
With fusion of the mesenteric layers the small intestine retains a long and mo-
bile mesentery; however, the caecum and ascending colon become fused with 
the posterior abdominal wall.  
Associated with the embryological development of the small intestine a number 
of abnormalities can occur.  
Abnormal rotation of the intestinal loop may occur and this results in a volvulus 
where the blood supply to the loop is compromised, particularly when the base 
of the small bowel mesentery is shortened. On occasions there can be reverse 
rotation of the intestinal loop and the small intestine is found towards the right 
side of the abdomen, with the caecum and the large intestine to the left.  
Further abnormalities may include duplication of the intestinal loop with cysts. 
These cysts are most frequently found within the region of the ileum and they 
may vary from a long segment to a short one with a small diverticulum. Other 
abnormalities of the small intestine may be associated with defects within the 
abdominal wall.  
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An omphalocele (exomphalos) involves the herniation of the abdominal viscera 
through a defect within the umbilical ring.  
This defect often contains small bowel, and liver, stomach, spleen and gall 
bladder may also be included. The defect is thought to be caused by failure of 
the bowel to return to the body cavity following its physiological herniation be-
tween the sixth and tenth week of development. This defect may occur in up to 
2.5 per 10.000 births and it is associated with a high mortality22.
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3 Aetiology and Predisposing Factors for 
Adenocarcinoma of the Duodenum 
 
 
3.1 INTRODUCTION 
 
Primary Adenocarcinoma of the Duodenum arises from the Lieberkuhn epithe-
lium of the duodenal mucosa and it is a rare condition, accounting between 0, 
3% and 0, 5% of all gastrointestinal malignancies 1-3. Despite the duodenum is 
representing less than 
 10 % of the total length of the small bowel, this organ is the site of between 
25% and 45% of the small bowel cancers.  However cancer of the duodenum 
appeared to be more frequent in the proximity of the Ampulla of Vater periam-
pullary area, about 45 % of them demonstrated to arise in third and in fourth 
portions of this organ.  
Adenocarcinoma tend to arise in the duodenum rather than other parts of the 
small bowel maybe because is close to the ampulla of Vater. Although, ampul-
lary carcinomas are usually classified as tumours of the extra-hepatic biliary 
tract rather than the small bowel, duodenal adenocarcinomas tend to gather in 
the periampullary region. This clustering may implicate bile or its metabolites in 
the aetiology of adenocarcinoma at this site. 
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The incident rate of small bowel cancer varies among populations. Small bowel 
cancer and duodenal cancer rates high among the Maori of New Zealand and 
among ethnic Hawaiians, and low in India, Romania, and other parts of Eastern 
Europe.  
In most population-based registries, males have higher small bowel cancer inci-
dence rates than females. 
The incidence of the small bowel and duodenal cancer rises with age. The 
mean age at the diagnosis is typically about 60 +/- 10 years 23. 
3.2 PREDISPOSING FACTORS 
The predisposing factors for epithelial Neoplasms of the Duodenum can be di-
vided in two groups: 
 (a) Inflammatory Disorders, such as Crohn’s disease 
 (b) Genetic Disorders, familial adenomatous polyposis (FAP) or heredi-
tary non-polyposis colon cancer (HNPCC). 
Other general factors including occupational hazards and lifestyle factors such 
as smoking and alcohol intake were investigated in two European multicentre 
case-control studies 24, 25. A cohort of 70 patients diagnosed with small bowel 
adenocarcinoma (SBA) during the study period (1995–1997) was compared 
with 2070 matched controls. Beer and spirits intake were associated with small 
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bowel adenocarcinoma, with an odds ratio (OR) of 3.5 and 95% confidence in-
tervals (CI) of 1.5–8.0.  
However, there was no association between smoking or total alcohol intake and 
adenocarcinoma of the small bowel. In a second study of the same group, in-
vestigators identified occupational clustering of SBA. The strongest industrial 
risk factors for SBA were dry cleaning, manufacture of work wear, mixed farm-
ing (women), and manufacture of motor vehicles (men).  
A significantly increased risk of SBA was found among men employed as build-
ing caretakers (OR 6.7; CI 1.7 to 26.0) and women employed as housekeepers 
(OR 2.2; CI 1.1 to 4.9); general farm labourers (OR 4.7; CI 1.8 to 12.2); dockers 
(OR 2.9; CI 1.0 to 8.2); dry cleaners or launderers (OR 4.1; CI 1.2 to 13.6); and 
textile workers (OR 2.6; CI 1.0 to 6.8)  
 
TABLE 2.1 
Inflammatory Conditions Genetic Syndromes 
Crohn’s disease Familial adenomatous polyposis 
Coeliac Disease HNPCC 
 Peutz–Jeger 
 Neurofibromatosis 
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3.2.1 CROHN’S DISEASE 
Crohn’s Disease is an inflammatory bowel disease that affects mainly people in 
their 3rd and 4th decade of life. It has long been associated with a high incidence 
of adenocarcinoma of the small bowel and colon. The first case of duodenal 
adenocarcinoma was reported in 1987 26. Interestingly, when the surgical ap-
proach to the treatment of Crohn’s disease was changed from radical resection 
to bypass surgery, in literature has been described a high incidence of adeno-
carcinoma of duodenum in patients who underwent to bypass gastrojeju-
nostomy for duodenal stricture 27, 28. 
3.2.2 COELIAC DISEASE 
Long standing coeliac disease is associated with an increased risk of malig-
nancy, not only of intestinal lymphoma but also of duodenal adenocarcinoma. 
This is frequently manifested by loss of response to gluten withdrawn. It was 
suggested that the subgroup of coeliac patients not responding to gluten-free 
diet they were more prone to develop malignancy but this theory has never 
been scientifically proven 29,30. 
3.2.3 FAMILIAL ADENOMATOUS POLYPOSIS (FAP) 
Familial adenomatous polyposis (FAP) is the most common adenomatous poly-
posis syndrome. It is an autosomal dominant inherited disorder characterized by 
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the early onset of hundreds to thousands of adenomatous polyps throughout 
the colon.  
The genetic defect in FAP is a germline mutation in the adenomatous polyposis 
coli (APC) tumour suppressor gene, located on chromosome 5q21 31, 32. 
Multiple extra-colonic manifestations of FAP have been described, representing 
all three embryological layers. These manifestations can be either benign or 
malignant. 
Endodermal lesions include duodenal and small bowel polyps and carcinomas. 
Mesodermal abnormalities include desmoids tumours, osteomas, and dental 
abnormalities. 
Ectodermal lesions localize to the eye, brain, and skin appendages. 
Desmoid tumours of the abdominal cavity and duodenal adenocarcinoma are 
the most serious extra-colonic manifestations of FAP.  
It is estimated that some 10% of all FAP patients will develop desmoids, 
whereas 50–90% of FAP patients will suffer from duodenal adenomas predomi-
nantly concentrated on or around the major papilla. Desmoid tumours and duo-
denal carcinomas are major causes of death in those patients in whom a pro-
phylactic proctocolectomy has been performed 33. 
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Although some investigators suggest that the adenoma–carcinoma sequence, 
which is generally accepted for colorectal adenomas, also applies for the duo-
denal adenomas in FAP patients, it is not clear whether these patients should 
be screened for upper gastrointestinal adenomas. 
 Since these polyps are usually small, multiple, and difficult to remove, the 
benefit of endoscopic surveillance would be the early detection of cancer. En-
doscopic surveillance programmes grade the severity of the duodenal disease 
according to the Spigelman classification (stages 0-IV) to identify patients at risk 
of developing adenocarcinoma. Duodenoscopy can also be used therapeutically 
to remove polyps and thus reduce a patient’s Spigelman stage.  
However, a recent study has demonstrated that patients down staged from 
Spigelman stage IV demonstrated an increased rate of progression to severe 
disease.  Therefore, once a patient has been classified as having stage IV dis-
ease he should be treated as a high risk patient and a surgical treatment can be 
considered 34. 
The preferable surgical procedure for a FAP patient is demonstrated to be a 
duodenectomy with pancreas preservation, and a pancreaticoduodenectomy 
only for a patient with proven malignancy 35. 
3.2.4 HEREDEDITARY NON-POLYPOSIS COLORECTAL CAN-
CER (HNPCC) 
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Hereditary non polyposis colon cancer (HNPCC) also known as Lynch syn-
drome, is an autosomal dominant genetic disorder caused by germline muta-
tions in mismatch repair (MMR) genes.  
This can result in an increased risk of primary colorectal cancer, but also cancer 
of the breast, endometrium, and ovary. Patients with HNPCC may also have an 
increased risk of pancreatic cancer 36. 
The genes involved in mismatch repair include MSH2, MLH1, PMS1, PMS2 and 
MSH6/GTBP 37. 
The phenotype observed, as a result of defective DNA mismatch repair, ap-
peared as Microsatellite Instability (MSI), which consists in a presence of insta-
bility at microsatellite regions in the MMR-deficient cells. Those microsatellite 
instability (MSI) is used as a diagnostic marker for loss of MMR activity in tu-
mour cells.  
However the risk of developing primary small bowel cancer in HNPCC patients  
has been demonstrated 38,  only few case reports documented a clear correla-
tion between duodenal cancer and hereditary non polyposis colorectal cancer 
39.  
3.2.5 PEUTZ-JEGHERS SYNDROME  
Peutz-Jeghers syndrome (PJS) is an autosomal dominant disorder character-
ized by melanocytic macules of the lips, buccal mucosa, and digits; multiple 
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gastrointestinal hamartomatous polyps; and an increased risk of various neo-
plasms, including PC.  
It is often caused by mutations in the LKB1/STK11 tumour suppressor gene on 
chromosome 19p13.  STK11 is a tyrosine kinase and is known to be located 
both in the nucleus and the cytoplasm of all human tissue.  STK11’s primary 
function is energy homeostasis and it is the primary kinase of AMP Kinase 
(AMPK) 40. 
 As a tumour suppressor gene, STK11 has been shown to cause apoptosis in 
intestinal epithelial cells appearing as an important key-regulator of the G1- 
checkpoint.  
In literature, cases of malignant transformation of solitary Peutz-Jeghers type 
hamartomatous polyp of duodenum have been reported 41, 42. 
3.2.6 NEUROFIBROMATOSIS (von Recklinghausen’s Disease) 
 Neurofibromatosis type 1 (von Recklinghausen’s disease) is an autosomal 
dominant genetic disorder characterized by cafe au lait spots, pigmented 
hamartomas (Lich nodules) of the iris, and cutaneous neurofibromas.  
While the association between neurofibromatosis and neuroendocrine tumours 
is well described, there are numerous reports suggesting that the association 
between duodenal adenocarcinoma and neurofibromatosis may not be fortui-
tous and that duodenal cancer should be considered in the differential diagnosis 
of gastrointestinal symptoms in patients with neurofibromatosis 43.  
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FIGURE 1 
SPIGELMAN CLASSIFICATION 
Points Polyps Polyps size 
(mm) 
Histology Dysplasia 
1 1-4 1-4 Tubular Mild 
2 5-20 5-10 Tubulovillous Moderate 
3 >20 >10 Villous Severe 
 
STAGE I, 1-4 points; STAGE II, 5-6 points; STAGE III, 7-8 points; STAGE IV, 
9-12 points 
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4 
Clinical Presentation and Diagnosis 
 
4.1 CLINICAL PRESENTATION  
In general, primary duodenal cancer manifests itself with non-specific gastroin-
testinal symptoms. The main group of symptoms include pain, obstructive 
symptoms, symptoms related to bleeding, and symptoms related to effects on 
adjacent organs such as obstructive jaundice. 
Other clinical symptoms and signs such as palpable mass, loss appetite and, 
weight loss are less frequent. However, a good proportion of the patients are 
asymptomatic at the time of diagnosis. 
Abdominal pain is not specific, can be related to stretching of the serosa or neu-
ral invasion of the tumour. The pain is usually described as dull ache, intermit-
tently associated to food intake, it can be radiated to the back and it is poorly 
localised.  
The non specificity of the pain can mislead the clinician to consider as causes of 
this pain more common pathologies such as  colonic diverticulosis, gallstones 
and “irritable bowel syndrome” and,  therefore to delay the diagnosis. 
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Bleeding from duodenal cancer is rarely acute. Generally, patients with duode-
nal cancer have chronic microcytic iron deficiency anaemia with related symp-
toms of fatigue and weakness. 
Obstructive bowel symptoms are rare and they can occur as result of luminal 
obstruction as concentric growing tumour. However, another reason for obstruc-
tion is intussusceptions. In literature, it has been described cases of duodenoje-
junal intussusceptions caused by distal carcinoma of duodenum 44. 
Despite being a non-specific symptom, weight loss has been highlighted by 
Bakaeen as an indicator of poor outcome even after a potential curative resec-
tion. The reason of this it could be explained by the fact that weight loss appear 
as late symptom reflecting a late stage in the natural history of the disease 14. 
4.2 DIAGNOSTIC MANAGEMENT  
It is often difficult diagnose early duodenal cancer because of their non-specific 
and insidious presentation. The diagnostic work-up can be long, expensive and 
it always involves an invasive procedure. The choice of the diagnostic investiga-
tion depends on the presenting symptoms. Patient presenting with obstructive 
symptoms are investigated radiologically, while patients presenting with iron-
deficiency anaemia will benefit from an endoscopic approach. 
 
 
4.2.1 COMPUTED TOMOGRAPHY OF ABDOMEN 
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A Computed Tomography of the abdomen (CT) with intravenous and oral con-
trast can identified benign and malignant tumour of the proximal and distal duo-
denum. The value of a CT scan is not only to diagnose a cancer but also in all 
biopsy-confirmed cases in evaluation of the extension of the disease. 
Upper gastrointestinal ulceration is quite common and the presence of malig-
nancy in duodenal ulcer is rare. However, ulcer located in the distal part of the 
duodenum should be viewed as suspicious for malignancy.  
The important value of CT scan is not only to diagnose duodenal abnormality 
but also to evaluate the extent of the disease and staging. The appearance of 
duodenal cancer on CT scan can be similar of the appearance of adenocarci-
noma of the colon and includes: filling defects and polypoid mass. 
4.2.2 BARIUM RADIOLOGY 
Upper gastrointestinal barium radiology is still the most frequent modality used 
in the work-up of upper gastrointestinal symptoms. However, the correct diag-
nosis with barium radiology in patient with duodenal cancer is achieved in only 
50% of cases. The main reason of this is due to suboptimal distensibility and 
the presence of overlapping segments. 
 
 
4.2.3 OESOPHAGUS-GASTRO-DUODENOSCOPY (OGD)  
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The upper gastrointestinal endoscopy has become the first line examination for 
duodenal cancer related symptoms. The value of endoscopy as primary diag-
nostic method for the upper GI tract has been established. The introduction of 
fibreoptic endoscopy has extended the range of interventions undertaken in the 
duodenum such as endoscopic mucosal resection (EMR). However, the asso-
ciation of Familial Adenomatous Polyposis (FAP) with high risk of duodenal car-
cinoma has also raised the role of the upper GI endoscopy as surveillance tool 
45, 46.   
This new role of endoscopy showed an increased number of case reports of 
early duodenal cancer in the recent years 47, 48. The macroscopic type of early 
duodenal carcinoma is classified by criteria similar to those used to classify 
early colorectal carcinoma. (Fig 1) 
Detection of superficial epithelial flat lesions during conventional endoscopy re-
mained a challenge, even for experienced endoscopists. In the last few dec-
ades Japanese researchers have advocated the use of dye spraying tech-
niques. Magnifying Chromoendoscopy (MC) has revolutionised the detection of 
flat lesions in the mucosa and, when used in a targeted fashion, allows the un-
masking of the type of lesion and its borderlines. Furthermore, the use of mag-
nifying endoscopes during chromoendoscopy allows a detailed surface analysis 
of suspected lesions and prediction of the dignity of the lesions using the so-
called pit pattern classification. (Fig2-4) 
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The efficacy of magnifying chromoendoscopy (MCE), not only in differentiating 
between epithelial neoplastic and non-neoplastic lesions, but also in accurately 
determining invasion depth of early  cancer, has widely been demonstrated 49, 
50. 
However, magnifying chromoendoscopy (MCE) is operator-dependent and  
labour-intensive, and requires the use of staining solutions, spraying catheters, 
and several water rinses. These requirements have hampered its wider accep-
tance, particularly in Western countries, despite its demonstrated effectiveness. 
Fig 5 
Recent years have seen the advent of narrow band imaging (NBI) as new en-
doscopic technique to characterise epithelial lesions. This is an innovative opti-
cal technology that uses interference filters to spectrally narrow the bandwidth 
used in conventional white light medical videoscopy.  
NBI, using optical filters, highlights surface structure and superficial mucosal 
capillaries. This can allow an enhanced appreciation of the mucosal pattern or 
‘pit pattern’ and of superficial microvessel networks. This has led to NBI useful-
ness being assessed in many endoscopically accessible organs where superfi-
cial epithelial neoplasia may occur including the oro-pharynx, oesophagus, 
stomach, duodenal ampulla, lung, colon and bladder, with promising results 51, 
52. 
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A meta-analysis by East et al. suggests that NBI may be considered an equiva-
lent to chromoendoscopy for lesion characterization in both the oesophagus 
and colon as form of ‘electronic dye-spray 53. 
In a more recent study Sakamoto et al. comparing directly magnify chromoen-
doscopy with narrow banding imaging in evaluating the depth of invasion of co-
lorectal studies, confirmed that NBI had comparable accuracy to pit pattern 
analysis using MCE 54, 55.  
In conclusion, magnifying endoscopy with NBI or MCE improves the view of mi-
crovessels of the mucosa in early neoplastic lesions of the duodenum. These 
techniques can predict the depth of the mucosal lesion with the advantage to 
obtain more detail information about the lesion; information that are useful for 
the endoscopists in order to make a decision towards or against an endoscopic 
resection.  
 
 
 
 
 
 
 
 
 
 
Primary Adenocarcinoma of the Duodenum  Clinical Presentation & Diagnosis  
 
 
31 
 
 
 
 
 
 
FIGURE 1 
 
 
 
 
Macroscopic classification of early duodenal adenocarcinoma 
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IGURE 2 
 
 
 
 
 
 
 
 
 
 
 
 
F
  
it Patterns classifications 
IGURE 3 
 
P
 
 
 
F
 
 
Pit pattern type Characteristics 
I roundish pits 
II stellar or papillary pits 
III S small roundish or tubular pits (smaller than type 
I pits) 
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III L large roundish or tubular pits (larger than type I 
pits) 
IV branch-like or gyrus-like pits 
V non-structured pits 
 
haracteristics of the different pit pattern types C
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00, well differentiated 
denocarcinoma in tubular adenoma, 
mucosal, ly0, v0) 
 
 
 
 
FIGURE 5 (A) Endoscopic findings 
of the depressed-type FAP-associated 
early duodenal carcinoma after the 
spreading of dye (0.1% indigo car-
mine). The tumour is located in the 
second portion of the duodenum, and 
the margin of the depressed lesion is 
irregular. (B), (C) Histologic findings of 
an endoscopically resected specimen. 
(H-E stain x20, x1
a
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Total gastrointestinal examination has been possible with DBE using an endoscope for 
the small intestine. This endoscope was developed by Yamamoto et al. . Such an ex-
amination was not possible using a conventional device. The total length is 2300 mm 
for the standard type, and the effective length is 2000 mm. A selection can be made 
This system has been developed for patients in whom insertion of the endoscope is 
difficult in the colorectal region. Therefore, all treatment devices for the large intestine 
can be used in this system. In addition, as this system has the regular DBE functions, 
stable manipulation is possible even in the deep portion of the duodenum.  DBE has 
been proved to be useful for carrying out duodenal endoscopic treatment, especially in 
The double-balloon enteroscope features two balloons, one attached to the distal end 
of the scope and the other attached to a transparent tube sliding over the endoscope. 
When inflated with air, the balloons can grip sections of the small intestine and 
"shorten" the small intestine by pleating it over the endoscope. Sequential shortening of 
the small intestine over the endoscope and advancement of the endoscope enables a 
Recent studies concluded that the detection rate and complication rate of DBE are ac-
ceptable. They found that DBE is a valuable modality, with a pooled detection rate of 
68.1 percent for all small intestinal disease. 
 
 
4.2.4 DOUBLE BALOON ENDOSCOPY (DBE) 
55
between two types which differ in outer diameter.  
areas distal to the major duodenal papilla. 
comprehensive examination of the entire small intestine. FIG 6  
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 Inflammatory lesions and vascular lesions are the common findings in patients with 
suspected mid-gastrointestinal bleeding in Eastern and Western countries, respec-
tively, according to DBE. Although DBE failed to identify a proportion of lesions, the 
performance of DBE is acceptable because the symptoms of a significant proportion of 
patients without positive findings would not recur during follow-up. They noted that DBE 
is considered to be a safe procedure with few complications, most of which are minor. 
 
FIGURE 6 
 
Fig 1 - Double Balloon Enteroscope & Overtube System  Fujinon Medical Inc. 
 
 
 
TABLE 1 
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TNM Classification 
Primary tumour (T) 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
T1 Tumour invades lamina propria or submucosa 
T2 Tumour invades muscularis propria or size >1 cm  
T3 Tumour invades through the muscularis propria into the subserosa 
without penetration overlying serosa 
T4 Tumour perforates the visceral peritoneum or directly invades 
other organs or structures (includes other loops of the small intes-
tine, mesentery, or retroperitoneum more than 2 cm, and the ab-
dominal wall by way of the serosa; for the duodenum only, in-
cludes invasion of the pancreas) 
Regional lymph nodes (N) 
NX Regional lymph nodes cannot be assessed 
T1 No regional lymph node metastasis 
T2 Regional lymph node metastasis 
Distant metastasis (M) 
MX Distant metastasis cannot be assessed 
M1 No distant metastasis 
M2 Distant metastasis 
 
 
 
TABLE 2 
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Stage Grouping using TNM system 
Stage 0 Tis N0 M0 
T1 N0 M0 Stage I 
T2 N0 M0 
T3 N0 M0 Stage III 
T4 N0 M0 
Any T N1 M0 Stage IV 
Any T Any T M1 
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5 
Molecular Pathogenesis and Prognostic fac-
tors of Adenocarcinoma of Duodenum 
 
 
5.1 MOLECULAR PATHOGENESIS 
 
Little has been published about carcinogenesis of duodenal adenocarcinoma 
due to rarity of this disease. Although the small intestine makes up approxi-
mately 75% of the length and 90% of the mucosal surface of the gastrointestinal 
tract, small bowel adenocarcinoma (SBA) occurs 50 times less frequently than 
colorectal adenocarcinoma 56. 
Despite this intriguing biological difference in the incidence of small bowel ade-
nocarcinoma (SBA) and colorectal adenocarcinoma, few investigations into the 
mechanisms of small bowel carcinogenesis have been conducted. A number of 
theories have been postulated to explain the relative protection of the small in-
testine from the development of carcinoma; however, none have been proven. 
Proposed protective factors have generally centred around two concepts. First, 
the rapid turnover of small intestinal cells results in epithelial cell shedding be-
fore the accumulation of the genetic damage critical to carcinogenesis.  
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Second, exposure of the small intestine to the carcinogenic components of our 
diet is limited because of the small intestine’s rapid transit time, lack of bacterial 
degradation activity, and relatively dilute alkaline environment. 
Stepwise progression of human cancer has been clinically well recognised. 
Several types of premalignant lesions, such as dysplasia and hyperplasia, can 
be detected in diverse organs prior the appearance of fully malignant tumours. 
The premalignant lesions are caused either by genetic alterations which include 
monoclonal expansions of the cells, or by environmental factors, such as viral 
infection, which include polyclonal expansion of the cells. Subsequently, accu-
mulation of genetic alterations occurs in one or few of the premalignant cells 
and the cells convert into malignant ones of clonal origin and produce a primary 
tumour.   
However, at early stage of primary tumour expansion, the cells are not invasive 
and metastatic. Then, new clones with invasiveness and metastatic ability ap-
pear as result of further accumulation of genetic alterations in the cells.  
Since cancer is attributed to genetic alterations accumulated in the cells, it is 
indispensable to identify genes whose alterations accumulate during tumour 
progression to understand the molecular mechanism of progression of cancer.  
FIG 1 
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FIGURE 1 
 
Stepwise malignant progression of human cancer associated with accumulation of genetic altera-
tions in cells.  
 
 
Over the last 3 decades, a number of genes that are genetically altered in hu-
man cancer cells have been identified.  
In 1990, Fearon and Vogelstein proposed a model of successive genetic 
changes leading to colorectal cancer (CRC), in which a number of genes were 
involved, including APC (adenopolyposis coli), k-Ras, DCC, and p53 57. FIG 2  
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FIGURE 2 
 
According to the model proposed by Vogelstein different genes are involved in each step of the 
progression from normal mucosa to metastatic cancer. 
 
 
 The original proposal stressed that mutations in these genes were essential for 
the development of CRC, rather than specifying the exact sequence of 
changes.  
Subsequent research over almost 10 years has revealed much information on 
the function of the key genes in the model, which will be reviewed first. 
The APC gene product was originally thought to be involved in cell adhesion by 
binding to b-catenin, a known component of the adherent junction complex. 
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 Later on, it appeared that APC co-localized with the microtubular system and 
bound to other molecules, such as EB-1; it was also, shown to induce apoptosis 
in APC-deficient cell lines. 
Over the past few years, a role of APC in the Wnt signalling pathway has 
emerged. In this pathway, APC acts as a partner molecule of b-catenin, which is 
degraded and inactivated through binding to APC. Upon the binding of a Wnt 
peptide to its receptor, a signal is instigated, which through the dishevelled gene 
product inactivates glycogen synthase kinase 3β (GSK-3 β). This blocks phos-
phorylation of β-catenin and prevents its binding to APC;  
β-catenin accumulates and starts acting as a co-transcription factor, providing 
the transactivation domain for the transcription factor Tcf-4. The mutated and 
truncated APC product is unable to bind and titrate b-catenin, so that Wnt sig-
nalling in an APC mutated cell becomes deranged 58,59. 
More recently, one of the genes inappropriately activated in a deranged Wnt 
signalling system turned out to be c-myc 60. This may shed light on the reason 
why this signalling pathway is so crucial for normal function of a colonic epithe-
lial cell and may also explain some of the hitherto enigmatic effects of APC on, 
for example, apoptosis 
The association of Familial Adenomatous Polyposis  (FAP) with duodenal can-
cer has facilitated a better  understanding the natural history of the duodenal 
polyposis and the risk of develop duodenal cancer 61. 
In recent years, different hypothesis regarding the carcinogenesis of the duode-
nal cancer has been proposed. 
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 It has been suggested two different pathways of carcinogenesis: one character-
ized by an adenoma-carcinoma sequence and the second one by a de novo 
cancer. Epidemiologic, histologic and histochemical observations of FAP-
associated carcinoma suggest an adenoma-carcinoma sequence in the duode-
num similar to that in the colon 62.63. 
 In that sequence, the inhibition of apoptosis through an altered expression of 
regulatory proteins plays an important role. As a result, regulatory proteins, 
such as p53, bcl-2, and cyclooxygenase 2 (COX2), have thus been suggested 
to be possible predictors of malignant transformation in colorectal adenoma. 
 However, somatic mutations of APC, K-ras, and p53 genes have been reported 
in duodenal adenomatosis, which differ from those found in colorectal cancer 64, 
65.  
Because carcinogenesis and tumour progression are considered to be the con-
sequence of accelerated somatic alteration of oncogenes related to cell kinetics, 
such mutations may contribute to the increased risk of duodenal cancer in FAP 
subjects. It thus seems to be valid to identify proteins that are related to the cell 
kinetics of duodenal adenomatosis to elucidate their malignant potential. 
 Cell apoptosis is regulated by various inhibitors and promoters. In a recent 
study by Esaki et al., bcl-2 and p53 were selected as representative inhibitors of 
apoptosis since these proteins have been shown to play a key role in either the 
early or the late stage of colorectal carcinogenesis 64. However, this study failed 
to demonstrate any difference in bcl-2 and p53 immunoreactivity between FAP 
and non-FAP subjects. 
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 Those results indicated that duodenal adenoma in FAP subjects do not have a 
higher proliferative activity or a smaller degree of apoptosis when compared 
with those in non-FAP subjects. The inverse correlation between the endo-
scopic grade and the proliferative activity seems to be compatible with the static 
nature of ampullary adenoma in FAP. 
Kashiwagi et al. 66 indicated a close correlation between p53 overexpression 
and a high-grade dysplasia of duodenal adenoma in FAP subjects. p53 may 
thus be a putative marker of duodenal adenoma and it thus requires a close 
surveillance in FAP subjects. 
The adenomatous components have also been reported to be present in around 
50 % of duodenal sporadic cancers 67. However, there are few reports concern-
ing the carcinogenesis of sporadic duodenal carcinoma. 
 Achille et al. 68 investigated 12 cases of sporadic duodenal carcinoma for ge-
netic anomalies involved in the pathogenesis of gastrointestinal malignancy. 
Those anomalies included chromosome allelic losses; Ki-ras and p53 muta-
tions; and microsatellite instability such as mismatch repair genes (MMR). 
 This study showed that the majority of cases had frequent chromosomal 
changes and mutations of Ki-ras and p53 genes, while widespread subtle al-
terations due to mismatch repair deficiency occurred in a minority. 
 The results proved that sporadic duodenal non-ampullary cancers share similar 
molecular pathogenic pathways to colorectal cancers. However, the small num-
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ber of cases in the study did not allow the assessment of the prognostic value of 
the molecular variable through a survival analysis. 
 Although the prevalence of cancer of the duodenum is low compared with colo-
rectal cancer, these similarities in the two cancers suggest that they may share 
many of the genetic changes of carcinogenesis.  
If the two cancers differ in either the type of genetic changes or the frequency of 
these changes, then it may be hypothesised that the small bowel is resistant to 
the genetic events that occur in colorectal cancer. 
As in colorectal cancer, a recent study suggested that small bowel adenocarci-
nomas are characterised by a defect in DNA mismatch repair (MMR), which re-
sults in DNA microsatellite instability (MSI) 69.  
Microsatellite instability (MSI) is characterised by the accumulation of changes 
in the length of simple repeated nucleotide sequences known as microsatellites, 
caused by mutations in MMR genes such as MutS homologue 2 (hMSH2), MutL 
homologue 1 (hMLH1), post meiotic segregation increased 1 (hPMS1), hPMS2, 
and hMSH6. Although MSI is a hallmark of hereditary nonpolyposis colorectal 
cancer syndrome (HNPCC), in which mutations of one or more MMR genes are 
found in 90% of the cases, it has also been reported in approximately 10% of 
sporadic colorectal adenocarcinomas 70. 
Recent studies counting early onset duodenal carcinoma in children showed 
presence of germline biallelic MMR mutations. Biallelic mutations in PMS2 ac-
counted for majority of cases in families with MMR-D (25/50 families, 50%), 
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while MLH1 and MSH6 each accounted for 20% of families, and MSH2 ac-
counted for 10% of families 71-74. 
Other oncogenic signalling pathways that are active in colorectal cancer include 
the epidermal growth factor receptor (EGFR), vascular endothelial growth factor 
receptor (VEGFR), and phosphatidylinositol 3-kinase (PI3K)/AKT pathways. 
A recent extensive study on small bowel adenocarcinoma suggested that altera-
tions in DNA MMR pathways are common in SBAs, similar to what is observed 
in large bowel adenocarcinomas.  
Furthermore, this study showed a high percentage of tumours expressing both 
EGFR and VEGF which suggests that patients with this rare cancer may benefit 
from therapeutic strategies targeting EGFR and VEGF receptor (VEGFR). 
However, in recent study involving the role of β-catenin and E-cadherin in ade-
nocarcinoma of small bowel, Wheeler et al. did not detect mutations in the Mu-
tational Cluster Region MCR of the APC gene, and this suggests that adeno-
carcinoma of the small intestine may follow a somewhat different genetic path-
way to colorectal cancer, although still often involving alterations associated 
with β-catenin and E-cadherin.  
Over expression of p53 was a relatively frequent finding and, as in colorectal 
cancer, reflects its important role in the carcinogenesis of the small intestine 75, 
76. 
Those recent findings show intriguing differences from colorectal cancers with 
respect to APC mutations, suggesting that molecular mechanism leading to the 
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development of duodenal adenocarcinoma may be different than those leading 
to colorectal cancers. 
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5.2 PROGNOSTIC FACTORS 
 
Prognostic factors associated with survival in patients with primary adenocarci-
noma of the duodenum still remain controversial. 
Different retrospective series have evaluated the prognostic impact of specific 
clinico-pathological factors for duodenal adenocarcinoma. FIG 1 
Considering the heterogeneity of the symptomatology of the primary duodenal 
adenocarcinoma, it is difficult to give to a specific symptom a particular prognos-
tic value. 
However, Hurtuk et al. 77 described how presenting symptoms can be indicative 
of advance disease, proving that patients presenting, at least with four symp-
toms had a worse outcome despite aggressive surgical resection. 
In the literature, the presenting symptoms are related to the site of the duode-
num involved by the tumour. However, jaundice at presentation seems to be 
reported as sing of advance disease and, therefore a symptom that can affect 
the survival after resection. 
Rotman et al. 78 stressed the importance of anaemia as indicator of better prog-
nosis, even though the data was not statistically significant. The explanation of 
this result can be explained by the fact that patients with anaemia come to the 
attention of the doctor sooner. 
Bakaeen et al. found that weight loss was predictive of worse survival 14. 
The length of the presenting symptoms has also a prognostic importance. In-
deed, the adenocarcinoma of duodenum is normally presenting with non-
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specific symptoms: causing an index of suspicious very low and, substantially a 
delay in the diagnosis. 
In literature, the average symptoms were present before the diagnosis for a 
minimum of 3 months and in some cases up to 6-8 months. 
Delcore et al. 79 reported that patients who had a length of symptoms of 4 
months or longer before the diagnosis have a worse 2-year survival rate.  
Chung et al. 18 recently reported White Blood Count (WBC) as an independent 
factor for survival from 1 through 5 years. WBC was not significant factor for 
survival only at 1 year, but tended to correlate with survival at 2 and 5 years. 
In the univariate survival analysis, the white blood cell (WBC) was significantly 
correlated with survival at 6 months, 1, 2 and 5 years.  
In literature, the issue on survival of patients with duodenal adenocarcinoma 
have still many areas of controversy: the prognostic significance of size and lo-
cation of the tumour, histological grading, staging of the disease and nodal 
status. 
The significance of the primary location in regard to the prognosis is still debat-
able. Lowell et al. 80 reported longer survival rate among patients with distal tu-
mour, whereas  
Schn et al. 81 and Stell et al.82 reported longer survival in patients with proximal 
tumours. However, it seems evident in literature that the distal tumours have a 
better prognosis. 
A better prognosis for distal tumour can have an embryological explanation. The 
proximal duodenum, which includes the supra-papillary and the peri-papillary 
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duodenum, is part of the foregut, while the distal or infra-papillary duodenum 
origins from the midgut. Tumours originating from the foregut are well known to 
be more aggressive of the one from the midgut. 
 Barnes et al. 7 found that adenocarcinoma of the duodenum behaves similarly 
to colon cancer, whereas Rose et al. 6 and Sarela et al. 15 reported a similarity 
to gastric cancer. 
Ryder et al. 83 found that tumour size is an important independent prognostic 
factor, through a correlation between the diameter of the lesion and survival: 
greater the diameter, shorter the survival.  
The hypothesis behind this results was supported by the fact that larger tu-
mours have been present longer and having more time to metastasize and in-
volve the adjacent structures. Interestingly, Hurtuk et al. 77 found that tumours 
larger of 3.5 cm were less likely to be invasive and on the contrary smaller tu-
mours tend to be more aggressive. 
Resection margins are considered as prognostic factor. In literature, patient who 
had an R0 resection (margins not involved) survives significantly longer than 
those with non-R0 resection (margin involved) independently from stage of the 
disease. 
Lymph node status is a prognostic factor for survival, since nodal metastases 
have been associated with poor prognosis. Bakaeen et al. 14 reported a clear 
association between nodal metastasis and decrease survival (68% vs 22%). 
 The median number of nodes were higher in the radical surgery (6 nodes) 
compared with the limited resection group (2 nodes).  
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However, despite potential downstaging in the limited resection group no differ-
ence of survival was noted when compared with the radical resection group.  
The importance to have an accurate lymph node staging in duodenal adenocar-
cinoma in comparison with antral gastric cancer was evaluated by Sarela et al. 
15. The incidence of nodal positivity was similar in the duodenal and in the antral 
gastric cancer groups. However, the duodenal cancer group had fewer patients 
with 15 or more lymph nodes assessed (47%vs 64%). The authors concluded 
that for the duodenal cancer, examination of 15 or more lymph nodes improved 
prognostic discrimination by the pN category. 
  The American Joint Committee on Cancer (AJCC) requires at least six re-
gional lymph nodes assessment for duodenal or small bowel cancer.  
Sarela et al. introduced the possibility of stage migration. The expectation of 
having an improvement in disease specific survival in both the node-negative 
and node-positive duodenal carcinoma group who have > 15 lymph nodes was 
not fulfilled. Indeed, in the node negative group there was a 25% improvement 
of in survival when > 15 lymph nodes were assessed, but surprisingly   the 
nodes positive group’ patients who  
had < 15 nodes had a 17% improvement of survival.  
Therefore, the importance of total lymph node sampling remains unclear.  
A recent study from Massachusetts General Hospital showed for the first time 
the superior prognostic importance of perineural invasion versus lymph node 
involvement. This single-centre retrospective study included 169 patients with 
duodenal adenocarcinoma.  
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They collected demographic, clinical and pathological data including the lymph 
node ratio (LNR) and the perineural invasion (PNI). In this study, univariate 
analysis demonstrated that nodal involvement, LNR, advance tumour stage, 
and perineural invasion were each associated with significant decrease in over-
all survival. However, a multivariate analysis identified perineural invasion as 
the most independent predictor of survival 20. 
Perineural invasion (PNI) is the process through which cancer cells invade the 
perineural spaces of surrounding nerves and is frequently present in pancreatic 
and prostatic cancer. This process involves many signalling molecules from 
various signalling pathways; these signalling molecules called neurotrophins are 
produced by both the cancer cells and the nerves. Once the cancer cells have 
invaded the nerves, they are able to thrive within the neuronal spaces.  
Several neurotrophins, including NGF, BDNF, and NT-3, have been implicated 
in promoting tumour cell invasion and may be key mediators in the pathogene-
sis of PNI 84. 
 In a recent molecular study has been reported that chemokine 
CX3CL1/Fractalkine act as neurotrophic factors attracting receptor positive pan-
creatic tumour cells to disseminate along peripheral nerves 85.  
In pancreatic cancer the incidence of PNI can account even for a 100 % in-
volvement of intrapancreatic nerves and nearly 70 % of extrapancreatic nerves 
85, 86. 
In the Massachusetts General Hospital data the perineural invasion was present 
in 40% of the patients with duodenal adenocarcinoma. 
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 These results were associated with an absence of concordance between per-
ineural invasion and nodal involvement in more than one third of the patients 
raising the hypothesis which hat the perineural invasion may due to different 
pathogenic pathways.  
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TABLE 1 
Overview of literature with analysis of prognostic factors for survival in patient after potentially 
curative resection for duodenal cancer 
 
Author [ref] (year) Number of cases % 5-year OS Predictors 
Barnes [7] (1994) 36 29 pN 
Rose [6] (1996) 42 60 pN 
Santoro [8] (1997) 65 25 pT 
Tumour location 
Sohn [81] (1998) 48 53 Margin involvement 
Location 
Yeo [87] (1998) 17 59 pN 
Ryder [83] (2000) 27 43 pT 
Grading 
Bakaeen [14] 
(2000) 
68 a 54 pT 
pN 
Margin involvement 
Weight loss 
Tocchi [16] (2003) 47 23 pN 
Sarela [15] (2004) 72 71a pN 
Age 
Hung [88] (2007) 11 16.6 TNM stage 
Cytology 
Cigarette smoking 
AST 
Lee [89] (2008) 28 44 pT 
pN 
Zhang [17] (2010) 59 33 pN 
Margin involvement 
 
Poultsides [19] 
(2011) 
122 48 pN 
LNR 
Chung [18] (2011) 14 6.7 Total bilirubin 
TNM stage 
Grading 
WBC 
CDT 
Cecchini [20] 
(2011) 
103 42 Perineural invasion 
Verona study 
(2012) 
25 71 POC 
Grade 
Margin involvement 
a Disease specific survival (R0 resection only), pN pathological nodes states, pT patho-
logical tumour states, LNR lymph node ratio, WBC white blood cell count, AST Alanine 
transaminase, CDT cancer-directed-treatment, POC postoperative complications. 
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6 
Early Duodenal Adenocarcinoma and Endo-
scopic treatments 
 
6.1 INTRODUCTION 
 
With the increasing prevalence of endoscopy, there have been an increasing 
number of reports of duodenal lesions. However, conventional surgery is often 
selected for duodenal adenoma because the incidence of duodenal cancer is 
relatively low, and its endoscopic treatment is difficult compared with that of the 
stomach and large intestine because of anatomical features and the long dis-
tance to the lesion. 
 
6.2 ENDOSCOPIC TREATMENTS 
Recent advances in the field of endoscopic examination have made possible 
not only to diagnose duodenal cancer at early stage but also to treat it. 
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6.2.1 ENDOSCOPIC MUCOSAL RESECTION (EMR) 
Endoscopic mucosal resection is a method developed by Tada et al. 90 for the 
treatment of superficial stomach tumours.  
At the present time, EMR provides for the safe resection of polyps, flat lesions 
of the stomach including adenoma and early adenocarcinoma. In this method, 
0, 9% NaCl solution   or sodium hyaluronate solution are injected into the submu-
cosal beneath a mass with endoscopic needle. Since the wall of the duodenum 
is thinner than that of the stomach, the injection of saline solution into the duo-
denal wall adjacent or beneath the tumour should aim to raise the tumour from 
the submucosal and serosal layers.  
This method prevents the occurrence of intramural burns even if multiple pieces 
are removed in a piecemeal fashion.  
Ulcers produced by electrocoaugulation after pre-injection of normal saline are 
all confined to the submucosal layers, whereas nearly half of those produced by 
electrocoaugulation without injection of saline involve the muscle or deep layer 
of the bowel wall. Those results confirm that this technique is safe for the treat-
ment of intramural lesions of the intestine. 
Despite the indications for endoscopic treatment of early cancer in the oe-
sophagus, stomach and large bowel are been well defined, the indications for 
treatment of early cancer in the duodenum are still not established.  
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Satake et al. 91 reported that no lymph node metastasis was found in 14 patients 
with intra-mucosal carcinoma of the duodenum, whereas, it was detected in one 
of 18 patients (5.6%) with submucosal tumours.  
Nagatani et al. 92 studied the indications for endoscopic treatment from the 
viewpoint of lymph nodes metastasis by analysing 128 lesions in 127 patients of 
early duodenal carcinoma reported in Japanese literature from 1968 to April 
1992 93. They reported that the rate of lymph node metastasis is 0% for intra-
mucosal cancers and 5% for sub-mucosal cancers. 
 These findings suggested that it is unlikely that intra-mucosal cancers are me-
tastatasize to lymph node, although early cancer which infiltrates submucosal 
layers has high chance to have positive lymph nodes. Therefore, it has been 
established that endoscopic treatment for early duodenal cancer is indicated 
only for intra-mucosal cancers. 
On the basis of these histological results, Nagatani supported that peduncolated  
tumours (Type Ip ) of 20 mm or less in diameter, sessile tumour (Type Is) tu-
mour of 5 mm or less, superficial lesions (Type IIa+ IIb) of 10 mm or less are 
indications radical endoscopic treatment of early duodenal cancer. FIG 1, 2  
 
 
 
 
FIGURE 1 
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 Macroscopic classification of early duodenal adenocarcinoma. 
 
However, another review of literature concluded that protruding or elevated tu-
mours less than 50 mm can be removed completely but the Type II depressed 
lesions with or without marginal elevation of 10 mm or larger should be removed 
surgically since high chance to have lymph nodes metastasis 94. 
 Taken together with previous studies, duodenal cancers appearing as a pro-
truded lesion of 20 mm or less and a flat depressed tumour of 10 mm or less 
are considered to be indicators for radically curative endoscopic treatment. 
The recognized complications of EMR include bleeding, pain, perforation, and 
stricture formation. Bleeding is the most common complication and usually oc-
curs during or within 24 hours of the procedure. Early bleeding in the duodenum 
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has been reported in up to 33% of patients, and it is the most common compli-
cation associated with this procedure. 
 The reported frequency of bleeding during an EMR for a duodenal adenoma 
range from 4% to 33%.95-97.The frequency of delayed bleeding can be reduced 
by prevention measures such as APC or clipping. Primary closure of the re-
sected area by clips is preferable to APC because it does not increase tissue 
injury after EMR.  
FIGURE 2 
 
Endoscopic images of the endoscopic mucosal resection (EMR) procedure. (A) Adenoma in the 
second part of the duodenum. (B) EMR procedure. (C) The site after the EMR 
 
 
6.2.2 ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD) 
More recently, Endoscopic submucosal dissection (ESD) has emerged as a 
novel technique for achieving en bloc resection for superficial neoplasms limited 
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to the mucosa. The advantage of this technique is to increase the ability to 
achieve en-bloc dissection. (Fig 3) Recent retrospective comparative trials 
showed that ESD achieved higher rates of en bloc resection and curative resec-
tion than EMR 98-100.  
ESD is technically difficult procedure to perform because of the anatomical 
properties of the duodenum. 
Honda et al. 101, recently described 9 duodenal lesion treated by ESD. All cases 
were limited to the mucosal layer and resected in en bloc with a mean time of 
operation 85.2 minutes, and localised in the second portion of duodenum. Five 
cases were carcinoma in adenoma and four were adenoma. A double balloon 
endoscope (DBE) was used in order to improve the control of the tip of the en-
doscope since it has been proven to be difficult to maintain the distance be-
tween the tip of the scope and the duodenal lesion. The mean diameter of the 
tumours was 23.8 mm (median 22 mm, range 12–39 mm) and that of the re-
sected specimens was 32.4 mm. FIG. 3 
They experienced duodenal perforation in two cases as a complication of ESD. 
In one case, it occurred during ESD and was immediately treated by clipping. In 
the other case, delayed perforation led to surgical treatment. 
Delay perforation has a well know complication due to exposure of the duodenal 
wall to pancreatic juice and bile. Administration of protease inhibitors could be 
useful for prevention of delayed perforation. 
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Honda et al. advocated that the combine use of small-caliber-tip transparent 
hood  
(ST hood) and hook knife can make possible to resect superficial duodenal le-
sion en block with ESD technique. However, ESD is difficult to standardize due 
to high level of endoscopic skills required to perform it; considering that endo-
scopist’s experience affects the outcome of ESD. 
FIGURE 3 
 
En-block resection of a 3.0 cm adenocarcinoma in adenoma by ESD technique. 
 
 
6.3 SUMMARY  
In conclusion, the majority of benign lesions in the duodenum can be resected 
using the standard EMR technique. This treatment method helps to reduce the 
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need for open surgery and offers an acceptable complication rate that can be 
managed by endoscopy. 
 However, in presence of early duodenal cancer presenting as protruded lesions 
bigger than 20 mm and superficial lesions bigger of 10mm endoscopic treat-
ment should be abandon in favour to a surgical resection due to higher risk of 
nodal involvement. Some institutions indicate as first choice of endoscopic re-
section ESD for duodenal lesions exceeding 10 mm in diameter and in which 
en-bloc resection is desirable 102-103. 
ESD is feasible and useful for superficial duodenal neoplasms. However, it is 
still a technically demanding, time-consuming procedure and associated with a 
high risk of complications. 
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7 
Primary Nonampullary Duodenal Adenocar-
cinoma- Verona Experience 
 
 
7.1 INTRODUCTION  
Primary adenocarcinoma of the duodenum is a rare condition, accounting be-
tween 0.3% and 0.5% of all gastrointestinal malignancies 1. Despite the duode-
num is representing less than 10 % of the total length of the small bowel, it is 
the site of between 25% and 45% of the small bowel cancers 2. Cancer of the 
duodenum appears to be more frequent in the periampullary area, but has been 
also shown to arise in the third and fourth duodenal portion 4. Since the symp-
toms are non-specific and similar to other benign conditions, the diagnosis is 
often difficult and delayed. Nonetheless, duodenal carcinoma has a reported 5-
year survival rate for resected tumours between 25% and 75% 5-10,17,18,20, which 
is significantly better than that for cancer of the ampulla of Vater (46%) and the 
head of pancreas (10%) 11,12. In the last decade, different studies evaluated the 
correlations between clinical, pathological and treatment variables in order to 
identify specific prognostic factors associated with survival 13-20. These studies 
showed that sex, age, tumour size and location, grade, stage, resection mar-
Primary Adenocarcinoma of the Duodenum  Verona Experience 
 
 
65 
 
gins, weight loss, and white blood cells count can influence survival signifi-
cantly.  
However, due to a low incidence of the disease in the general population, the 
debate on prognostic factors in duodenal adenocarcinoma is still open. There-
fore, questions have been raised especially on the prognostic significance of 
nodal status and of the absolute number and ratio of involved lymph nodes 15, 
and a recent report established perineural invasion as another important inde-
pendent prognostic factor 20. The purpose of the present study was to evaluate 
clinico-pathological features and analyse the main prognostic factors in patients 
with duodenal adenocarcinoma observed at our institution. 
7.2 PATIENTS AND METHOD 
This study was approved by the Institutional Review Board. The clinical records 
of all patients diagnosed with primary duodenal adenocarcinoma and referred to 
the unit of General Surgery B, University of Verona, between January 1990 and 
December 2009 were reviewed. The diagnosis was confirmed by histological 
examination of all resected specimens or by endoscopic biopsies. Patients with 
adenoma and malignant neoplasms other from adenocarcinoma were excluded. 
Demographic and clinical details, surgical and pathological data were collected 
from the patient notes. Pathological data included tumour size, grade, and 
stage. Pathological staging of duodenal adenocarcinoma was based on the 
American Joint Committee on Cancer (AJCC) system, 7th edition. A tumour 
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comprising two different degrees of differentiation was recorded as the category 
of poorer differentiation.  
Lymph node ratio (LNR) was calculated dividing the total number of lymph 
nodes harbouring metastasis by the total number of resected nodes, cut-off 
points were chosen according to the existing literature 104. Additional collected 
parameters included perineural invasion (defined as tumours cells within any 
layers of the nerve sheath or perineural space), and the presence of lymph-
vascular invasion (defined as microscopic lymphatic invasion, vascular invasion, 
or both).  
A curative resection was defined as a microscopically negative resection with 
no gross evidence of residual disease (R0 resection). A resection with curative 
intent was ultimately defined as a palliative intervention if the margin was micro-
scopically (R1) or macroscopically (R2) positive. Palliative treatment also in-
cluded biliary and gastrointestinal bypass, biopsy and exploration alone.  
Postoperative morbidity and mortality were defined as occurrence of complica-
tions and death within 30 days of the operation, respectively.  
Postoperative pancreatic fistula (PF) was defined according to the International 
Study Group on Pancreatic Fistula (ISGPF) 105. Follow-up information was ob-
tained from our electronic database or through telephone interviews.  
7.2.1 STATISTICAL ANALYSIS  
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Data were analyzed using the SPSS software (version 19.0; SPSS, an IBM 
company, Chicago, IL, USA). Distribution of continuous variables was reported 
as median and range. Categorical variables were presented as numbers and 
percentages. 
 Overall survival time was calculated from the date of operation/pancreatic re-
section to the date of last follow-up/death. 
 Cumulative event rates were calculated using the method of Kaplan and Meier. 
Univariate analyses were performed using the log-rank test to compare differ-
ences between categorical groups. A Cox proportional hazards model was de-
veloped using relevant clinico-pathologic variables in a direct enter fashion (uni-
variate inclusion criteria of p<0.150) to determine the association of each with 
overall survival. P-values were presented with hazard ratios and 95% confi-
dence intervals. 
 For univariate and multivariate analysis, the variables tumor size, resection 
margins, tumor grade and stage were dichotomized as appropriate (≤3 cm ver-
sus >3 cm, R0 versus R1-R2, G1 versus G2-G3, and Stage I-II versus Stage III-
IV). Statistical significance was determined by a p-value of less than 0.05. 
7.3 RESULTS  
7.3.1 DEMOGRAPHIC  
Thirty-seven patients with primary adenocarcinoma of the duodenum were iden-
tified. There were 21 men and 16 women with a median age of 57 years (range 
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38-83 years). Only one patient (2.5%) developed duodenal adenocarcinoma fol-
lowing colectomy for Familial Adenomatous Polyposis (FAP).  
The majority of patients had cancer arising in the descending part of the duode-
num- D2 (66.7%) and the remaining of the patients the cancer arose from the 
horizontal part of the duodenum- D3 (32.4%). Our data did not show any cases 
of duodenal adenocarcinoma located at the proximal and distal portion of the 
duodenum (D1 & D4).    
The median Body Mass Index (BMI) was 22.6 (17.0-31.6), a median CA19.9 
level at initial presentation was 24 U/ml with a range between 1 and 96.957 U/ml 
(Units per millilitre). TABLE 1 
7.3.2 DIAGNOSIS  
The most common presenting symptoms were non-specific upper abdominal 
pain (70.3%), weight loss (62.2%), jaundice (27%), episodes of maelena 
(16.2%) and anaemia (3%). 
In patients who underwent palliative resection, the most frequent initial symp-
toms were weight loss (75%) and abdominal pain with vomiting (62.5%), com-
pared to abdominal pain (72%) and Jaundice (36%) in patients with resectable 
disease.  
7.3.3 OPERATIVE TREATMENT AND COMPLICATIONS  
Twenty-five patients (68%) underwent potentially curative resection, 8 patients 
underwent to biliary bypass, 1 patient had an exploratory laparotomy, and 3 pa-
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tients received a non surgical palliative treatment. Non surgical palliative treat-
ment included chemotherapy with supportive treatment. 
The 25 patients underwent curative resection were equally demographically dis-
tributed comprised 14 male and 13 female with a median age of 54 years (38-
83 years). 
Whipple’s Procedure was performed in 9 patients (36%) and a Pylorus Preserv-
ing Pancreas Duodenectomy (PPPD) was performed in 16 patients, independ-
ently by the location of the tumour. 15 patients (60%) had tumours in the sec-
ond portion of the duodenum while 10 (40%) patients had tumours in the third of 
the duodenum.  
The overall length of surgery was 360 minutes with a range between 180-630 
minutes. 
The median length of stay for the curative resection patients was of 14 days (9-
57), while the median length of stay after palliative treatment was 11.5 days (8-
27). 
Only 9 patients required postoperative blood transfusion. (26.5%) 
 No postoperative mortality was reported following those pancreaticoduodenec-
tomies. Overall postoperative morbidity was 52 % with a rate of 56% in the 
curative resection group and a rate of 50% in the bypass group. 
 In the curative resection group the most common postoperative complication 
was pancreatic fistula involving 4 patients (11.8 %).  Among the palliative group, 
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one or more complications developed in 4 patients (50%), with chest infection 
appearing to be the most common complication in this group of patients (25%).   
The median length of stay for the curative resection patients was 14 days (9-
57), while it was 11.5 days (8-27) after double bypass. 
No postoperative mortality was reported following surgery in both groups of pa-
tients. (Table 2) 
7.3.4 PATHOLOGICAL FINDINGS 
This analysis was restricted to patients who underwent a potentially curative re-
section. Five patients (20%) were stage I, six (24%) were stage II, eleven (44%) 
were stage III, and three (12%) were stage IV. Among the three metastatic pa-
tients, one had a single lung metastasis, one had a single liver metastasis 
treated with concomitant wedge resection, and one had a proximal jejunal loop 
metastasis, which was excised with the pancreaticoduodenectomy specimen. 
Pathological data are summarized in table 4 .  
17 of the curative resection were histopathologically confirmed as R0 (68%), six 
were R1 (24%) and only two resections (8%) were reported as R2. Nodal me-
tastases (pN1) were identified in 24 patients (64.8%). The median number of 
lymph nodes retrieved was 19 (range 5-63), while the median number of lymph 
nodes excised from the pN1 patient group was 22 (range 10-61).  
7.3.5 SURVIVAL  
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The overall median follow-up was 25 months (5-180). 13 patients (35.1%) had 
no evidence of disease, and these included three patients who are still alive for 
at least five years. Two patients (5.4%) died for an unrelated cause. Eight pa-
tients (21.6%) were alive with recurrent or stable disease, while 14 patients 
(37.8%) died of recurrent disease, of these only one patient survived more than 
5 years.  
The median survival of the overall population (N=37) was 70 months (95% CI 
41.7-98.2), the 5-year survival rate was 58.5%. 
 The median survival time for patient undergoing curative (R0) surgery was sig-
nificant longer (180 months, 95% CI NA) than those undergoing palliative sur-
gery (35 months, 95% CI 11.9-58.0), with 5-years survival rates of 76.6% and 
35.4% respectively (p=0.013, Figure 1). Univariate and multivariate analysis 
was restricted to the 25 patients who underwent potentially curative resections. 
TABLE 3 
Median follow-up in this subgroup was 27 months (6-180), with a median sur-
vival of 70 months (95% CI 14.0-125.9) and a 5-year survival rate of 71.1%. 
Univariate analysis showed tumour grade (p=0.05), the occurrence of postop-
erative and of abdominal complications (p=0.05 and p=0.013) to be significantly 
associated with survival (Figure 2,3). In particular, median overall survival was 
180 months (95% CI NA) in patients with G1 tumours and 70 months (95% CI 
50.4-89.5) in patients with G2-G3 tumours. Five-year overall survival was 100% 
for G1 tumours and 61.6% for G2-G3 tumours. Median overall survival was 180 
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months (95% CI NA) in patients with an uneventful postoperative course and 70 
months (95% CI 10.7-129.2) in patients with a complicated course. 
 Five-year overall survival was 100% for an uneventful postoperative course 
and 53.3% for a complicated postoperative course. Median overall survival was 
180 months (95% CI NA) in patients who did not develop abdominal complica-
tions and 52 months (95% CI 22.5-129.4) in patients who develop abdominal 
complications.  
Five-year overall survival was 100% in the absence of abdominal complications 
and 60% in patients who develop abdominal postoperative morbidity. 
 The best regression model resulted in same three variables being independ-
ently associated with survival. Hazard ratios were 1.345 (95% CI 1.28-1.91, 
p=0.03) for tumour grade, 1.781 (95% CI 1.10-2.89, p=0.037) for the develop-
ment of postoperative complications, and 1.878 (95% CI 1.21-3.08, p=0.029) for 
the development of abdominal complications.  
7.4 DISCUSSION 
The aim of this study was to address factors influencing the long term survival in 
patients with duodenal adenocarcinoma through a retrospective analysis of our 
institution in a 20 year period.  
The debate regarding prognostic indicators for primary duodenal adenocarci-
noma is still open, likely because of the very low incidence of this malignancy 
Primary Adenocarcinoma of the Duodenum  Verona Experience 
 
 
73 
 
and the small number of studies published in the last two decades 14-16,19,82-83,88-
89.  
In the present paper we retrospectively evaluated the clinical features of pa-
tients with primary duodenal adenocarcinoma observed at our institution and 
addressed the prognostic relevance of different surgical and pathological factors 
after potentially curative pancreaticoduodenectomy.  
Duodenal adenocarcinoma usually presents with non-specific symptoms, which 
may be attributed to more common gastrointestinal disorders (such as peptic 
ulcer) or malignancies (such as gastric adenocarcinoma). 
 In our series, the most common presenting symptoms were abdominal pain, 
nausea and weight loss, although 27% of patients developed jaundice. Similarly 
to other reports, tumors occurred more frequently in the second portion of the 
duodenum (67.6%) 17. 
 At a median follow-up of 25 months, overall survival of the study population, 
which included patients undergoing pancreaticoduodenectomy, double bypass, 
or best supportive care, was 70 months. 5-year survival rate was 58.5%. As ex-
pected, overall survival was significantly longer after R0 resections (180 
months) when compared to palliative resections (R1/R2) and bypass operations 
(35 months). 
 Survival rate after curative surgery was substantially greater than in the study 
by Zhang et al, who reported a median survival of 45 months, with a 5-years 
survival rate of 49.3% 17. 
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 In the study by the Massachusetts General hospital group, median survival of 
resected patients was 44 months (88% of R0 resections), with a 5-years sur-
vival rate of 42% 20. A number of factors have been considered to be of prog-
nostic value after potentially curative resection, including sex, age, tumor size 
and location, grade, stage, resection margins status, LNR, perineural invasion, 
weight loss and biochemical parameters (white blood cells, alanine aminotrans-
ferase). However, not all these findings were consistent among different reports. 
 The first factor which in our study was found to be related to survival on multi-
variate analysis was histological grade, with a hazard ratio of 1.345 and a p-
value of 0.03.  
In particular, 5-year overall survival was 100% in well differentiated tumors (G1) 
and 61.6% in moderately to poorly differentiated tumors (G2-G3). Data from 
other gastrointestinal malignancies generally support the relationship between 
the degree of differentiation and survival, but only few other papers confirmed 
this concept in primary duodenal adenocarcinoma, both in the resection speci-
men and endoscopic biopsy. 
The most relevant finding of the present analysis was that postoperative com-
plications impact significantly on survival.  
Five-year overall survival was 100% in patients with an uneventful postoperative 
course, and 53.3% in patients who experienced complications (hazard ratio on 
multivariate analysis of 1.781, p=0.037). Being abdominal complications the 
most relevant after pancreaticoduodenectomy, they were analyzed separately 
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and found to be likewise associated with survival (hazard ratio on multivariate 
analysis of 1.878, p=0.029).  
The most frequent abdominal complication was PF, with an incidence of 16%, 
followed by postoperative bleeding (8.8%). The influence of postoperative mor-
bidity on survival after tumor resection has been reported for patients with oe-
sophageal and colorectal cancer 106-110. 
 In this study, the specific mechanism through which postoperative complica-
tions impact on long-term results can only be speculated.  
Postoperative complications can induce a systemic inflammatory response and 
the release of cytokines and growth factors which, in turn, may affect tumor 
growth and influence the survival 111. 
 The degree of host inflammatory cell activity can be measured indirectly by 
markers related to inflammatory response. High systemic level of C-reactive 
protein has been associated with poor survival in patient undergoing potentially 
curative resection for pancreatic and colorectal cancer, and – similarly – an ele-
vated neutrophil/lymphocyte ratio has been shown to influence the disease re-
currence rate in oesophageal and colorectal cancer 112-114. However, given the 
retrospective nature of this analysis, these markers of inflammatory response 
could not been evaluated. 
 A recent study has also shown that a prolonged period of immunosuppression 
and angiogenic stimulation caused by intra- and post-operative blood transfu-
sion was independently associated with earlier cancer recurrence and reduced 
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survival after pancreatoduodenectomy for pancreatic ductal adenocarcinoma 
115. However, we did not find any correlation between blood transfusions and 
survival.  
Another potential cause of worse survival in patients with postoperative morbid-
ity and prolonged hospital stay may be a delay in adjuvant therapy. Other pa-
pers have reported an improved median survival for patients with adjuvant ther-
apy 116, but our series was unable to demonstrate a benefit. In particular, the 
frequency of adjuvant therapy was not different between patients with or without 
postoperative complications (data not shown).  
Despite patients who did not experience complications were referred to the On-
cologist earlier, this did not seem to affect survival (data not shown). These re-
sults, however, have to be interpreted with caution, and larger studies are nec-
essary to clarify the role of adjuvant therapy for primary duodenal adenocarci-
noma.  
Tumor stage was not a significant prognostic factor in our study. Three M1 pa-
tients were resected, in two of them (one with a single liver metastasis and one 
with a jejunal metastasis) the tumors could be completely resected. Further-
more, the presence of lymph node metastases did not show a significant asso-
ciation with decreased survival. These findings suggest that lymph node in-
volvement should not preclude an aggressive surgical resection as a potential 
curative treatment. Contrarily to our findings, different studies have reported an 
important impact of nodal status and LNR on survival. 
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Interestingly, Sarela et al. 15 described the importance of accurate lymph node 
staging in duodenal adenocarcinoma, raising the hypothesis that examination of 
15 or more lymph nodes can improve diagnostic discrimination by the pN cate-
gory.  
Resection margin status, which is generally believed to be critical to survival in 
duodenal adenocarcinoma, did not result to be a significant prognostic factor in 
the resected population.  
A recent large single-institution study of 169 patients from Massachusetts Gen-
eral Hospital reported perineural invasion (which was present in 40% of resec-
tion specimens) to be the strongest independent predictor of recurrence and 
overall survival. LNR and size of tumor failed to stratify prognosis 20.  
Contrary to this finding, the present study did not show a significant association 
between perineural invasion (present in 48% of resection specimens) and over-
all survival. Similarly, we demonstrated no difference in survival based on tumor 
size, lymph-vascular invasion, and LNR.  
As with any retrospective study, this analysis has certain drawbacks. A lack of 
defined criteria for determining the operative or chemotherapeutic modalities 
was a major limitation, along with the small number of patients included in the 
study. With this in mind, we remark that postoperative morbidity may influence 
long-term outcomes after potentially curative pancreaticoduodenectomy for pri-
mary duodenal adenocarcinoma. Despite substantial advancements in surgical 
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techniques, this operation is still demanding and should be performed in high 
volume centers, where an appropriate postoperative care can be delivered.   
 
 
 
 
TABLE 1 
 Demographic and clinical details of patients with duodenal adenocarcinoma 
Study population (N=37) N (%) 
Sex 
Male 
Female 
 
21 (56.8) 
16 (43.2) 
Age, median (range ) 57 (38-83) 
Body mass index, median (range) 22.6 (17.0-31.6) 
Presenting symptoms 
Abdominal pain 
Nausea/Vomit 
Jaundice 
Anemia 
Melena 
Weight loss 
 
26 (70.3) 
13 (35.1) 
10 (27.0) 
3 (8.1) 
6 (16.2) 
23 (62.2) 
Ca 19.9, median (range) 24 (1-96957) 
Tumour location 
D2 
D3 
 
25 (67.6) 
12 (32.4) 
Preoperative tumor stage (AJCC, rTNM) 
Stage I 
Stage II 
Stage III  
Stage IV 
 
5 (13.5) 
7 (18.9) 
16 (43.2) 
9 (24.3) 
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TABLE 2 
Surgical and pathologic details of patients operated (N=34) with duodenal adenocarcinoma 
 N (%) 
Surgical treatment 
Exploratory operation 
Palliative bypass 
Pancreaticoduodenecomy 
Surgery not performed 
 
1 (2.7) 
8 (21.6) 
25 (67.6) 
3 (8.1) 
Length of surgery, median, minutes 
(range) 
360 (180-630) 
Blood transfusion 
Yes 
No 
 
9 (26.5) 
25 (73.5) 
Tumor size, median, mm (range) 25 (10-65) 
Postoperative complications 
Yes 
No 
 
18 (52.9) 
16 (47.1) 
Pancreatic fistula 
Yes 
No 
 
4 (11.8) 
30 (88.2) 
Hospital stay, median, days (range) 14 (9-57) 
Adjuvant therapy 
Yes 
No 
 
18 (52.9) 
16 (47.1) 
Pathological  details, resected patients (N=25) 
 N (%) 
Lymph nodes resected, median (range) 19 (5-63) 
Lymph node ratio 
0 
>0 and <0.2 
≥0.2 
 
11 (44.0) 
11 (44.0) 
3 (12.0) 
Resection margins 
R0 
R1 
R2 
 
17 (68.0) 
6 (24.0) 
2 (8.0) 
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Lymph-Vascular invasion 
Yes 
No 
 
10 (40.0) 
15 (60.0) 
Perineural invasion 
Yes 
No 
 
12 (48.0) 
13 (52.0) 
Tumor grade 
G1 
G2 
G3 
 
7 (28.0) 
10 (40.0) 
8 (32.0) 
TABLE 3 
 Variables with a potential influence on survival in patients undergoing resection for duodenal 
adenocarcinoma 
 
Factor Univariate analysis (p-
value) 
Multivariate analysis (p-
value) 
Sex 0.280  
Abdominal pain 0.761  
Nausea/Vomit 0.918  
Melena 0.376  
Jaundice 0.793  
Fever 0.220  
Weight loss 0.616  
Anaemia 0.868  
Grade (G1 vs G2-G3) 0.050 0.912 
R-Status (R0 vs R1-R2) 0.152 0.071 
AJCC stage (II-II vs III-IV) 0.937  
Lymph node ratio 0.299  
Vascular invasion 0.250  
Perineural invasion 0.419  
Postoperative morbidity 0.050 0.087 
Adjuvant therapy 0.700  
 
 
 
 
TABLE 4 
stage * resection 
RESECTION  
Yes No Total 
STAGE I 5 0 5
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II 6 1 7
III 11 5 16
IV 3 6 9
Total 25 12 37
 
 
TABLE 5 
Overview of literature with analysis of prognostic factors for survival in patient after potentially 
curative resection for duodenal cancer 
 
Author [ref] (year) Number of cases % 5-year OS Predictors 
Barnes [7] (1994) 36 29 pN 
Rose [6] (1996) 42 60 pN 
Santoro [8] (1997) 65 25 pT 
Tumour location 
Sohn [81] (1998) 48 53 Margin involvement 
Location 
Yeo [87] (1998) 17 59 pN 
Ryder [83] (2000) 27 43 pT 
Grading 
Bakaeen [14] 
(2000) 
68 a 54 pT 
pN 
Margin involvement 
Weight loss 
Tocchi [16] (2003) 47 23 pN 
Sarela [15] (2004) 72 71a pN 
Age 
Hung [88] (2007) 11 16.6 TNM stage 
Cytology 
Cigarette smoking 
AST 
Lee [89] (2008) 28 44 pT 
pN 
Zhang [17] (2010) 59 33 pN 
Margin involvement 
 
Poultsides [19] 
(2011) 
122 48 pN 
LNR 
Chung [18] (2011) 14 6.7 Total bilirubin 
TNM stage 
Grading 
WBC 
CDT 
Cecchini [20] 103 42 Perineural invasion 
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(2011) 
Verona study 
(2012) 
25 71 POC 
Grade 
Margin involvement 
a Disease specific survival (R0 resection only), pN pathological nodes states, pT patho-
logical tumour states, LNR lymph node ratio, WBC white blood cell count, AST Alanine 
transaminase, CDT cancer-directed-treatment, POC postoperative complications. 
FIGURE 1  
Kaplan-Meier survival curves of patients undergoing radical surgery (R0 pancreati-
coduodenectomy, n=17) versus palliative surgery (R1/R2 pancreaticoduodenectomy or 
bypass, n=16) 
 
Radical surgery: median overall survival = 180 months (95% CI NA) 
Palliative surgery: median overall survival = 35 months (95% CI 11.9-58.0) 
p=0.013 (Log-rank test) 
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NB: the patient who underwent exploratory laparotomy was not included in the analysis 
(17+16+1=34) 
 
 
FIGURE 2 
 
Kaplan-Meier survival curves comparing patients within the resection group by tumour 
grade. Five-year overall survival 100% vs. 61.6% for G1 and G2-G3 tumours, respec-
tively. 
 
 
G1: median overall survival = 180.0 months (95% CI NA) 
G2-G3: median overall survival = 70.0 months (95% CI 50.4-89.5) 
p=0.050 (Log-rank test) 
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FIGURE 3 
 
Kaplan-Meier survival curves comparing patients within the resection group by postop-
erative recovery (uneventful/complicated). Five-year overall survival 100% vs. 53.3% 
for uneventful and complicated postoperative course, respectively 
 
Uneventful course: median overall survival = 180.0 months (95% CI NA) 
Complicated course: median overall survival = 70.0 months (95% CI 10.7-129.2) 
p=0.050 (Log-rank test) 
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8 
The Role of chemo-radiotherapy & Palliative 
endoscopic stent in Duodenal Adenocarci-
noma  
 
 
8.1 INTRODUCTION 
 
Primary malignancy of the duodenum is rare. As result, our knowledge of the 
natural history, ideal management and prognosis of patients with primary duo-
denal cancer is limited compared to other gastrointestinal malignancies. Previ-
ously published data suggests that radical surgery with curative intents is the 
only curative treatment.  
In literature, the involvement of periduedenal structures and distant metastasis 
appear to be the main reason for non resectability of the lesion.  
In this chapter we will analyse the effects of adjuvant chemotherapy in influenc-
ing the overall survival of patients underwent potentially curative surgery. We 
will also consider the value of palliative duodenal stent in patients with non-
resectable disease reported in literature. 
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8.2 THE ROLE OF CHEMO-RADIOTHERAPY IN DUO-
DENAL 
 ADENOCARCINOMA 
Little information exists in literature about the effect of adjuvant chemotherapy 
and radiotherapy on overall survival in patients with node-positive duodenal 
adenocarcinoma treated with pancreaticoduodenectomy. The cause of this poor 
reporting in literature is mainly due to the rarity of the disease in the general 
population.  
 The results with chemotherapy seem to be disappointing in term of improving 
the overall survival in patients underwent to potentially curative surgery. Addi-
tionally, very few data on the activity of anticancer agents are also available for 
patients with advanced disease.  
In different studies on small bowel adenocarcinoma, only a small percentage of 
patients underwent adjuvant chemo-radiotherapy.  
In the largest retrospective series of small bowel adenocarcinoma from the Na-
tional Cancer Data Base, only 15% of patients with duodenal adenocarcinoma 
received radiotherapy, while 21% received chemotherapy 117. 
Retrospective studies have indicated that chemotherapy prolongs overall sur-
vival in patients with advanced small bowel adenocarcinoma but there is no 
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agreed frontline regimen owing to a lack of randomized trials 118,119. Most avail-
able data from literature are case reports or small retrospective studies  involv-
ing  old chemotherapy regimens. 
In a large multicentre study involving 11 hospitals, Zaana et al. 120 studied three 
different chemotherapy regiments to treat 154 patients with advanced small 
bowel adenocarcinoma.  
One group of patients underwent to infusion of Leucovorin and 5-fluorouracil (5-
FU) alone or with cisplatin (LV5FU2 regiment, LVFU2-cisplatin); FOLFIRI sub-
group including  Leucovorin, 5-fluorouracil, and irinotecan; the FOLFOX regi-
men with Leucovorin, 5-fluorouracil and oxaliplatin or cisplatin. This study 
showed that overall survival was best in the FOLFOX subgroup, although the 
difference did not reach statistical significance, due to lack of power. 
 The other important finding of this study was that in the platinum-based chemo-
therapy subgroup, the overall survival was significantly longer with FOLFOX 
than with LV5FU2-cisplatin.  
Another study reported that treatment with 5-FU and a platinum agent was 
highly effective and recommended this combination as frontline treatment for 
patients with metastatic small bowel adenocarcinoma 125. 
A recent prospective phase II trial enrolling 30 patients, has evaluated the bene-
fit of capecitabine in combination with oxaliplatin (CAPOX) in patients with ad-
vanced adenocarcinoma of small bowel. 
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This therapy combination (CAPOX) has given interesting results with a median 
time to pregression of 11.3 months, and a medial overall survival of 20.4 
months.  
Since the combination therapy CAPOX has been well tolerated and highly effec-
tive, the author suggested that this combination should represent a new stan-
dard for the treatment of patients with advanced small bowel adenocarcinoma. 
 These results indicate that small bowel adenocarcinoma is more sensitive to 
oxaliplatin than to cisplatin that its behaviour may resemble that of colorectal 
cancer more than that of gastric tumours. Indeed, survival of patients with ad-
vanced colorectal cancer was improved by combining 5-FU with oxaliplatin 126 
but not with cisplatin 127. Conversely, both oxaliplatin and cisplatin are active on 
advanced gastric cancer 128,129. 
A recent study from the Johns Hopkins Hospital analysed the effects of the ad-
juvant chemo-radiotherapy in patients with node-positive duodenal adenocarci-
noma.  All 14 patients received adjuvant external beam radiation therapy, and 
all were offered fluorouracil-based concurrent and maintenance chemotherapy.  
Only one patient received concurrent fluourouracil and cisplatin. The median 
follow-up was 12 months for patients who died and 42 months for those who 
survived. The median survival for all patients was 41 months, with a 5-year sur-
vival rate of 44%. Local control for patients treated with adjuvant chemo-
radiation therapy in this study was 93%.  
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Although this study is underpowered due to small number patients, it appears 
the adjuvant chemotherapy for node positive duodenal adenocarcinoma after 
pancreaticoduodenectomy may improve local control and median survival but 
does not appear to improve overall survival 130. 
As previously described for small bowel adenocarcinoma, new chemotherapy 
strategies are reported in literature. Unfortunately, those data are mainly coming 
from case reports and small retrospective studies. 
In a small retrospective analysis of 32 patients with duodenal adenocarcinoma, 
Kelsey et al.128 assessed the influence of preoperative and postoperative 
chemo-radiotherapy (CT-RT) on overall survival comparing with patients who 
had only surgical resection without further adjuvant therapy. 16 patients re-
ceived either preoperative (n = 11) or postoperative (n = 5) chemo-radiotherapy. 
Median radiotherapy dose was 50.4 Gy (range, 12.6-54 Gy). All patients treated 
with radiotherapy also received concurrent 5-fluorouracil-based chemotherapy. 
In his series, 2 of the 11 patients underwent preoperative chemotherapy had a 
complete pathological response, suggesting that duodenal adenocarcinoma 
may be chemo-radiation sensitive.  
 The main result of this study was a non significant difference on overall survival 
between patients receiving chemo-radiotherapy versus surgery alone (57% vs. 
44%, p = 0.42). 
 However, in patients undergoing R0 resection, CT-RT appeared to improve 
overall survival (5-year 83% vs. 53%, p = 0.07) 128. Therefore, comparing pa-
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tients who had CT-RT with patients who had surgery alone, the view is that  CT-
RT can have favourable outcomes in patients underwent radical surgery with 
clear margins (R0) can be supported. 
As previously described for small bowel adenocarcinoma, new chemotherapy 
strategies are reported in literature. Unfortunately, those data are mainly coming 
from case reports and small retrospective studies. 
Catania et al. 129 described a case of a patient with duodenal adenocarcinoma 
who underwent pancreatoduodenectomy followed by adjuvant chemotherapy.  
The tumour seemed to be resistant to eight bi-weekly cycles of 5-
fluorouracil/leucovorin/oxaliplatin (FOLFOX-4), and a subsequent 5-FU 200 
mg/m2/ die continuous-infusion concomitant with radiation therapy. However, a 
clinical complete tumour response to a second-line chemotherapy regimen with 
5-fluorouracil/leucovorin/irinotecan (FOLFIRI) was demonstrated. This case re-
port suggests that duodenal adenocarcinomas refractory to oxaliplatin could be 
highly sensitive to irinotecan-containing chemotherapy combinations.  
Another case report from Manfredi et al.130, described a patient with duodenal 
adenocarcinoma who at the time of the laparotomy the tumour was found to be 
invading the superior mesentery and therefore only a palliative bypass was per-
formed.  Palliative chemotherapy with FOLFOX 4 regiment (combination of ox-
aliplatin and infusional 5-FU/FA) was given for 4 months. 
 Since patient had a full clinico-radiological response from FOLFOX 4 regiment, 
a complete R0 duodeno-jejunal resection of the mass and reconstruction of the 
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mesenteric artery was performed. Surgery was followed by a 3 month course of 
adjuvant chemotherapy. Patient has been reported to be alive 27 months after 
surgery.  
Although it is case report, these findings suggested FOLFOX 4 regiment as po-
tential neoadjuvant therapy with the aim to down-staging or even complete ra-
diological response of patients with locally advanced duodenal adenocarci-
noma.  
The role of neoadjuvant chemo-radiotherapy in the management of unre-
sectable duodenal adenocarcinoma has been studied recently. Onkendi et al.131 
published a report in 2011 of 10 patients with localized advanced adenocarci-
noma treated with neoadjuvant chemotherapy. In this series, not all 10 patients 
had neoadjuvant chemotherapy and radiotherapy combined. Four patients un-
derwent curative R0 resection after chemotherapy alone. One patient did not 
have response to the neoadjuvant chemotherapy with FOLFOX. 
 Six patients received intraoperative radiotherapy (IORT); 4 of them survived 
more than 1 year, with 75% of these patients surviving more than 2 years. 
These outcomes are suggesting that intraoperative radiotherapy (IORT) may 
potentially prolong survival in this patient population.  
At present, there is no clear evidence showing a benefit from the use of adju-
vant chemotherapy following curative resection in patients with duodenal ade-
nocarcinoma.  
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All available data are drawn from small single-institution retrospective studies 
and case reports, which are all limited by significant selection bias. 
 
 Recent studies investigating the effect of colorectal regiments of chemotherapy 
(FOLFOX, FOLFIRI, combination of irinotecan, oxaliplatin and capecitabine with 
radiotherapy), showed an increased activity against tumour progression. It is 
likely that the proven benefit of adjuvant chemotherapy in colorectal cancer is 
being applied to clinical decision making for patients with duodenal adenocarci-
noma.  
Although, standardized chemotherapy protocols are not acknowledged in litera-
ture recent studies suggested a potentially beneficial effect of chemo-
radiotherapy regiments as neoadjuvant therapy with rescue surgery in an oth-
erwise unresectable and lethal disease.  A multi-institutional trial is needed to 
further elucidate the role of adjuvant and neoadjuvant therapy in this disease. 
 However, the main challenge for the near future is to identify a molecular 
marker involved in duodenal carcinogenesis with which to predict chemosensi-
tivity and thus to improve survival. Targeted therapy with mAbs against vascular 
endothelial growth factor or epidermal growth factor receptor (EGFR) has al-
ready shown significant efficacy on metastatic colorectal cancer and small 
bowel adenocarcinoma 132. 
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8.3 THE ROLE OF PALLIATIVE ENDOSCOPIC STENT IN 
DUODENAL ADENOCARCINOMA 
Malignant gastric outlet obstruction (GOO) is a late complication of gastric, pan-
creatic and duodenal carcinoma which can cause significant morbidity through 
persistent intractable nausea and vomiting, intolerance of oral feeding, and as-
sociated weight loss. Patients affected by GOO are at risk of aspiration and 
pneumonia. Obstruction reduces greatly the quality of life in these patients who 
have a limited life expectancy.  
The palliative treatment has the goal of maintaining the best quality of life pos-
sible during the terminal phase of the illness.  
When the life expectancy is predicted to be more than few days, traditionally 
palliative surgery through a gastrojejunostomy (GJ) has been the standard 
treatment. This treatment modality is associated with undoubted good functional 
outcome and relief of symptoms in almost all patients 133,134. Nevertheless, this 
carries a peri-operative morbidity as high as 35% and a mortality rate of about 
2% in later studies 134. Most patients also have delayed gastric emptying which 
often causes a prolonged hospital stay 135. 
During the last two decades, however, endoscopically placed self-expandable 
metallic stent (SEMS) have been increasingly used as minimally invasive mo-
dality for the palliative treatment of malignant duodenal obstruction.  
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Palliative endoscopic treatment of GOO with endoluminal self-expanding metal-
lic stents was first reported by Topazian et al. in the early 1990s 136. 
Stent placement for GOO has been suggested to be less invasive with a faster 
relief of symptoms compared to open or laparoscopic GJ. As a consequence, 
hospital stay should be shorter in the majority of patients with many of them be-
ing able to eat soft solids after 1–4 days. In several studies, this treatment has 
been evaluated as safe and efficient with a technical success rate of 90–100%, 
a clinical success rate of 67–100%, a rate of severe complications about 7% 
and non-severe complication rate about 20% 137,138. 
In literature, there are three recent systematic reviews 134,140 and two meta-
analysis 141,142 to assess the role of duodenal stent  in patients with GOO, which 
showed a positive influence of implementing endoscopic duodenal stent  in this 
group of patients. 
Only three randomized controlled trial comparing surgical gastro-jejunostomy 
(GJ) and endoscopic stent placement for palliation of malignant gastric outlet 
obstruction are reported in literature 143-145. All these randomized controlled trial 
showed that duodenal stenting is a safe means of palliating malignant gastric 
outflow obstruction. However, the Dutch SUSTENT Study Group suggested that 
the choice between surgical palliation and endoscopic stent is regulated by the 
life expectancy of the patients. 
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 In this randomized controlled study they recommended that despite slow initial 
symptom improvement, GJ was associated with better long-term results and is there-
fore the treatment of choice in patients with a life expectancy of 2 months or longer. 
Because stent placement was associated with better short-term outcomes, this treat-
ment is preferable for patients expected to live less than 2 months 147. 
Recurrent obstructive symptoms, necessitating a reintervention, seem occurring 
more frequently after stent placement than after GJ. The majority of recurrent 
obstructive symptoms after stent placement are caused by stent occlusion from 
either tumour in- or overgrowth, or food obstruction. 
 Duodenal stent obstruction by tumour in- or overgrowth remains a problem, es-
pecially when non-covered stents are used. The use of covered stents in the 
duodenum may however lead to a higher incidence of stent migration and may 
also lead to an increased incidence of biliary obstruction and even pancreatitis 
due to obstruction of the common bile duct and/or pancreatic duct by the cov-
ered device. 
Stent migration seems to occur in a shorter time period (range: 1–121 days) af-
ter stent placement than recurrent obstructive symptoms caused by tumour in- 
or overgrowth or food debris (range: 11–273days). In addition, stent migration 
seems to occur at a shorter time period and more frequently after placement of 
a covered stent (19%) than after placement of an uncovered stent. 
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Zheng et al. 142 in a recent meta-analysis suggested that GJ is a more expen-
sive procedure than endoscopic stent; however, there was inadequate data 
available to evaluate the potential cost savings of endoscopic stent over GJ.  
 Rate of gastric emptying are, however, only recorded after stenting, and the 
quantitative effect of stenting was thus not revealed. More detailed data on the 
effect of stenting on rate of gastric emptying is thus required, and can be used 
to improve the knowledge on the relation between GOO and obstructive symp-
toms. This is an important issue, since the relation between gastrointestinal 
symptoms and gastric emptying might be rather weak. 
Gastric emptying is a complex process involving grinding and emptying of the 
meal, and it is not likely that the re-establishment of passage is followed by a 
more rapid rate of gastric emptying in all subjects treated. In literature, only few 
studies analysed the predictive factors of survival in patients with malignant 
gastric outlet obstruction. 
 In a recent study, Jeurnink et al 134, collected prognostic factors on patients 
with malignant GOO, such as WHO performance status, prior or concurrent 
treatment of obstructive jaundice, extend of disease and weight loss. After a 
multivariable analysis, the WHO performance status appeared to be the only 
significant prognostic factor for survival.  
Therefore, the authors suggested that patient with a short survival (WHO 3-4) 
will benefit from the optimal short term outcomes of duodenal stent placement. 
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Patients with a longer survival (WHO 0-1) should however be considered for 
GJ.  
In palliative cancer care, improvement of QoL is a main treatment goal, and 
data on this issue are missing in most of the retrospective and prospective stud-
ies in literature. 
 Objective evaluation of gastric/duodenal function after stenting is still limited 
and only few studies have performed quantitative tests of gastric emptying.  
In conclusion, endoscopic stent is a safe and effective, minimally invasive and 
cost-effective option for the palliation of malignant GOO. However, larger ran-
domized controlled trials with longer follow-up data are needed to confirm these 
positive findings on endoscopic stent in palliative settings.  
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 Conclusion 
Non ampullary duodenal adenocarcinoma is a rare cancer representing less 
than of 0.5% of gastrointestinal malignancies and approximately 45 % of small 
bowel adenocarcinomas. 
The natural history of the duodenal adenocarcinoma is poorly understood, in 
comparison with the stomach and colo-rectum, the duodenum and small bowel 
seem to be relatively resistant to carcinogenesis. Although the small intestine 
provides the majority of the mucosal surface of the gastrointestinal tract, small 
intestinal adenocarcinoma is approximately 100 times less frequent than colo-
rectal cancer. 
 Several reasons have been discussed for this disparity, which mainly focus on 
a reduced carcinogen exposure of the small intestine due to the rapid transit 
and the highly diluted nature of its nutritional contents. However, recent molecu-
lar studies have showed that the molecular pathways of sporadic tumorigenesis 
differ in the small intestine compared to the large intestine.  
Hereditary syndromes or conditions that can predispose to duodenal adenocar-
cinoma include neurofibromatosis, hereditary non polyposis colorectal cancer 
(HNPCC), familial adenomatous polyposis (FAP) and its variants such as Gard-
ner’s Syndrome, Celiac Sprue, Puetz-Jeghers, Crohn’s Disease and Juvenile 
Polyposis Syndrome. 
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Primary duodenal adenocarcinomas are much rarer than those that arise from a 
secondary neoplastic process. Metastasis from the stomach, ovary, colon and 
uterus can involve the small bowel by direct means or via peritoneal involve-
ment. 
Metastatic tumours from breast, melanoma and lung appear to spread to the 
duodenum by blood and lymphatic pathways. 
Primary duodenal adenocarcinoma has a poor prognosis most likely due in part 
to a delayed diagnosis, which results from the difficulty making diagnosis, as 
patients often present with non-specific symptoms or signs not suggesting the 
need for upper gastrointestinal endoscopy. 
 Surgical resection is the only potentially curative treatment, but not all the pa-
tients in whom the tumour is removed will survive long term. Surgical interven-
tion has shown to provide a curative resection in 40-65% of patients. 
 The five year survival rate for non resected tumours being is 15-30% compared 
to 40-60% survival rate for those who had resection. 
 However, the prognosis for curatively resected duodenal adenocarcinoma is 
substantially better (5-year survival, 60%), than that for cancer of the ampulla 
(46%), distal bile duct (27%), or head of pancreas (10%). 
Due to the low incidence of the duodenal adenocarcinoma in the general popu-
lation, it has been difficult to determine which factors can influence the overall 
survival. 
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An assessment of the literature shows that our knowledge about duodenal ade-
nocarcinoma is based only on retrospective single or multi-centre studies. The 
aim of these studies was to determine those factors that influence the survival. 
The debate about the importance of the different factors on overall survival is 
still open.  
Therefore, several controversial issues remain to be studied including the sig-
nificance of the depth of invasion and degree of differentiation, the prognostic 
value of nodal involvement and the perineural invasion, the indications and type 
of adjuvant treatments.  
Our study is a retrospective review of 37 patients with diagnosis of primary duo-
denal adenocarcinoma referred to the Hepato-Pancreato-Biliary Institution of 
Borgo Roma Verona University Hospital (BRH) between January 1989 and De-
cember 2009. 
The   main aim or our study was to determine prognostic factors in patients who 
underwent potentially curative resection of their duodenal adenocarcinoma.  
A potentially curative resection was performed in 25 patients with a median age 
median age of 54 years (38-83 years). Perineural and lymph-vascular were pre-
sent in the 48% and the 40% of patients, respectively. Nodal metastasis (pN1) 
was identified in 13 patients (52%). 
Overall 5-year survival were 58.5% considering all the 37 patients 
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Survival was significant higher for patients who underwent curative resection 
(median overall survival 180 months; 5-year survival 71%) than those who un-
derwent palliative procedure (median overall survival 35 months) (p=0.013). 
Tumour grade (p=0.050), positive resection margins (p=0.152) and postopera-
tive complications (p=0.050) had a significant negative effects on the survival of 
the patients who underwent curative resection according to univariate analysis.   
Our series is the first study to evaluate postoperative morbidity as a potential 
prognostic factor of survival and recurrence after potential curative resection of 
duodenal adenocarcinoma. 
The influence of postoperative morbidity on long term survival after tumour re-
section has been reported for patients with oesophageal, colorectal cancer.  
The evidence from our study suggests that resectability of primary duodenal 
adenocarcinoma and a lower   tumour grade are associated with increase sur-
vival. However, postoperative morbidity seems to influence the overall long term 
survival in patient underwent curative resection of primary duodenal adenocar-
cinoma.
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